<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id>
<journal-title>Frontiers in Cell and Developmental Biology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell Dev. Biol.</abbrev-journal-title>
<issn pub-type="epub">2296-634X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1132060</article-id>
<article-id pub-id-type="doi">10.3389/fcell.2023.1132060</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cell and Developmental Biology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Transcription factors and potential therapeutic targets for pulmonary hypertension</article-title>
<alt-title alt-title-type="left-running-head">Yang et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2023.1132060">10.3389/fcell.2023.1132060</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Liu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wan</surname>
<given-names>Naifu</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gong</surname>
<given-names>Fanpeng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2198580/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Xianfeng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Feng</surname>
<given-names>Lei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Liu</surname>
<given-names>Guizhu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1921297/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Wuxi School of Medicine</institution>, <institution>Jiangnan University</institution>, <addr-line>Wuxi</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Vascular &#x0026; Cardiology</institution>, <institution>Ruijin Hospital</institution>, <institution>School of Medicine</institution>, <institution>Shanghai Jiao Tong University</institution>, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1742881/overview">Xia Gao</ext-link>, Baylor College of Medicine, United States</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2153702/overview">Meng Yu</ext-link>, Baylor College of Medicine, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/762390/overview">Jian Wu</ext-link>, Fudan University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Guizhu Liu, <email>liuguizhu@jiangnan.edu.cn</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Molecular and Cellular Pathology, a section of the journal Frontiers in Cell and Developmental Biology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>17</day>
<month>03</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>11</volume>
<elocation-id>1132060</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>12</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>03</day>
<month>03</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Yang, Wan, Gong, Wang, Feng and Liu.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Yang, Wan, Gong, Wang, Feng and Liu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Pulmonary hypertension (PH) is a refractory and fatal disease characterized by excessive pulmonary arterial cell remodeling. Uncontrolled proliferation and hypertrophy of pulmonary arterial smooth muscle cells (PASMCs), dysfunction of pulmonary arterial endothelial cells (PAECs), and abnormal perivascular infiltration of immune cells result in pulmonary arterial remodeling, followed by increased pulmonary vascular resistance and pulmonary pressure. Although various drugs targeting nitric oxide, endothelin-1 and prostacyclin pathways have been used in clinical settings, the mortality of pulmonary hypertension remains high. Multiple molecular abnormalities have been implicated in pulmonary hypertension, changes in numerous transcription factors have been identified as key regulators in pulmonary hypertension, and a role for pulmonary vascular remodeling has been highlighted. This review consolidates evidence linking transcription factors and their molecular mechanisms, from pulmonary vascular intima PAECs, vascular media PASMCs, and pulmonary arterial adventitia fibroblasts to pulmonary inflammatory cells. These findings will improve the understanding of particularly interactions between transcription factor-mediated cellular signaling pathways and identify novel therapies for pulmonary hypertension.</p>
</abstract>
<kwd-group>
<kwd>pulmonary hypertension</kwd>
<kwd>pulmonary vascular remodeling</kwd>
<kwd>transcription factors</kwd>
<kwd>endothelial cells</kwd>
<kwd>pulmonary arterial smooth muscle cells</kwd>
</kwd-group>
<contract-sponsor id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Guangdong Science and Technology Department<named-content content-type="fundref-id">10.13039/501100007162</named-content>
</contract-sponsor>
<contract-sponsor id="cn003">Fundamental Research Funds for the Central Universities<named-content content-type="fundref-id">10.13039/501100012226</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Pulmonary hypertension (PH) is a chronic life-threatening disorder characterized by progressive pulmonary arterial remodeling (<xref ref-type="bibr" rid="B99">Luks and Hackett, 2022</xref>) and inflammatory cell infiltration (<xref ref-type="bibr" rid="B169">Wang R. R. et al., 2022</xref>). According to the sixth World Symposium on PH, PH is clinically defined by elevated mean pulmonary arterial pressure (mPAP) &#x3e;20&#xa0;mmHg and normal left atrial pressure concomitant with pulmonary vascular resistance &#x2265;3 Wood Units (<xref ref-type="bibr" rid="B142">Simonneau et al., 2019</xref>). Structural and functional alterations of pulmonary arterial smooth muscle cells (PASMCs), pulmonary arterial endothelial cells (PAECs), pulmonary arterial fibroblasts, and inflammatory cells contribute to pathological pulmonary vascular remodeling (<xref ref-type="bibr" rid="B145">Southgate et al., 2020</xref>). Pulmonary vascular remodeling in PH involves complex mechanisms, including altered crosstalk between the vascular cells, hypoxia, sustained inflammation, resistance to apoptosis, increased proliferation and migration, and excessive activation of signaling pathways (<xref ref-type="bibr" rid="B58">Hassoun, 2021</xref>). Uncontrolled proliferation and hypertrophy of disordered pulmonary arterial cells represent hallmark features of pulmonary arterial remodeling. However, the underlying regulatory processes are not well defined.</p>
<p>Three classes of pharmacological therapies are currently available for PH treatment: prostaglandins, endothelin receptor antagonists, and phosphodiesterase type 5 (PDE5) inhibitors. Although these treatments improve pulmonary circulation and reduce hospitalization (<xref ref-type="bibr" rid="B68">Humbert et al., 2022</xref>), long-term follow-up shows that they do not reverse pulmonary arterial remodeling or decrease overall PH mortality (<xref ref-type="bibr" rid="B160">Thenappan et al., 2018b</xref>). Therefore, new targets and therapies for pulmonary vascular remodeling and PH are urgently required.</p>
<p>Transcription factors are sequence-specific elements that recognize and bind to DNA promoter regions, usually in complex with other proteins, guiding related genome expression. Numerous transcription factors and transcriptional coactivators have been identified as key regulators of PH and pulmonary vascular remodeling. However, a clear landscape of the role of transcription factors in PH progression is needed. Here, we review the involvement of transcription factors in various PH-related cellular mechanisms including in PASMCs, PAECs, pulmonary arterial fibroblasts and inflammatory cells (<xref ref-type="table" rid="T1">Table 1</xref>), and identify therapeutic targets for PH.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Summary of transcription factors in pulmonary hypertension.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Transcription factors</th>
<th align="left">Targets</th>
<th align="left">Functional cell types</th>
<th align="left">Molecular events and phenotypic features</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="5" align="left">STAT3</td>
<td align="center">CCNA2</td>
<td rowspan="5" align="center">PASMC</td>
<td rowspan="5" align="left">STAT3 promotes PASMC proliferation by binding to CCNA2 <xref ref-type="bibr" rid="B193">Zhang et al. (2020)</xref> and regulating BMPR2 <xref ref-type="bibr" rid="B16">Brock et al. (2009)</xref>, NFATc2 <xref ref-type="bibr" rid="B150">Sutendra et al. (2011)</xref>; <xref ref-type="bibr" rid="B39">Dromparis et al. (2013b)</xref>, PDGF <xref ref-type="bibr" rid="B126">Qian et al., 2018</xref>, c-myc <xref ref-type="bibr" rid="B6">Bai et al. (2006)</xref> expressing</td>
</tr>
<tr>
<td align="center">BMPR2</td>
</tr>
<tr>
<td align="center">NFATc2</td>
</tr>
<tr>
<td align="center">PDGF c-myc</td>
</tr>
<tr>
<td align="center">FoxO1</td>
</tr>
<tr>
<td rowspan="2" align="left">NFATc2</td>
<td align="center">Kv1.5</td>
<td rowspan="2" align="center">PASMC</td>
<td rowspan="2" align="left">NFATc2 induces PASMC proliferation and resistance to apoptosis <xref ref-type="bibr" rid="B125">Paulin et al. (2012)</xref>
</td>
</tr>
<tr>
<td align="center">Bcl2</td>
</tr>
<tr>
<td align="left">Smad2/3</td>
<td align="center">CDKs</td>
<td rowspan="2" align="center">PASMC</td>
<td rowspan="2" align="left">TGF-&#x3b2;/Smad and BMP/Smad signaling could participated in PASMC proliferation <xref ref-type="bibr" rid="B59">Hata and Chen (2016)</xref>; <xref ref-type="bibr" rid="B66">Huang and Huang (2005)</xref>; <xref ref-type="bibr" rid="B50">Gao et al. (2017)</xref>; <xref ref-type="bibr" rid="B180">Yang et al. (2010)</xref>
</td>
</tr>
<tr>
<td align="left">Smad1/5/8</td>
<td align="center">ID1</td>
</tr>
<tr>
<td rowspan="3" align="left">&#x3b2;-catenin</td>
<td align="center">TCF/LEF</td>
<td rowspan="3" align="center">PASMC</td>
<td rowspan="3" align="left">Wnt/&#x3b2;-catenin signaling contribute to proliferation phenotype of PASMCs <xref ref-type="bibr" rid="B9">Bernkopf et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">CyclinD1</td>
</tr>
<tr>
<td align="center">c-Myc</td>
</tr>
<tr>
<td rowspan="4" align="left">HIF-1&#x3b1;</td>
<td align="center">Notch3</td>
<td align="center">PASMC</td>
<td align="left">HIF-1&#x3b1; functioned as a pathogenic determinant of PASMCs <xref ref-type="bibr" rid="B91">Li et al. (2009)</xref>
</td>
</tr>
<tr>
<td align="center">Twist1</td>
<td align="center">PAEC</td>
<td align="left">HIF-1&#x3b1; activates Twist1 transcription and regulating EndoMT in hypoxia-induced ECs <xref ref-type="bibr" rid="B191">Zhang et al. (2018a)</xref>
</td>
</tr>
<tr>
<td align="center">IL-33</td>
<td align="left"/>
<td align="center">IL-33/ST2 enhances PAEC proliferation, adhesion, and angiogenesis <xref ref-type="bibr" rid="B148">Sun et al. (2017)</xref>; <xref ref-type="bibr" rid="B95">Liu et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left">HIF-1&#x3b1; binds to <italic>Twist1</italic> promoter regulating EndoMT in hypoxia-induced ECs <xref ref-type="bibr" rid="B191">Zhang et al. (2018a)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="left">HIF-2&#x3b1;</td>
<td rowspan="3" align="center">SPARC</td>
<td align="center">PASMC</td>
<td align="center">HIF-2&#x3b1; induces SPARC expression to increase PASMC proliferation <xref ref-type="bibr" rid="B164">Veith et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">PAEC</td>
<td align="left">EC HIF-2&#x3b1; knockout significantly reduces the progression of hypoxia-induced PH <xref ref-type="bibr" rid="B65">Hu et al. (2019)</xref>; <xref ref-type="bibr" rid="B26">Cowburn et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="left"/>
<td align="left">HIF-2&#x3b1; potently promotes EndoMT by contributing to vascular remodeling and NF-kB activation <xref ref-type="bibr" rid="B149">Sun et al. (2020)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="left">FoxO1</td>
<td align="center">p27</td>
<td rowspan="3" align="center">PASMC</td>
<td rowspan="3" align="left">FoxO1 activation reverses PASMC proliferation and PH development <xref ref-type="bibr" rid="B135">Savai et al. (2014)</xref>
</td>
</tr>
<tr>
<td align="center">Bcl6</td>
</tr>
<tr>
<td align="center">CyclinB1/D1</td>
</tr>
<tr>
<td align="left">PPAR&#x3b3;</td>
<td align="center">TGF-&#x3b2;1</td>
<td align="center">PASMC</td>
<td align="left">PPAR&#x3b3; inhibits TGF-&#x3b2;1-induced mitochondrial activation and PASMC proliferation <xref ref-type="bibr" rid="B18">Calvier et al. (2017)</xref>
</td>
</tr>
<tr>
<td rowspan="6" align="left">FoxM1</td>
<td align="center">SETD3</td>
<td rowspan="6" align="center">PASMC</td>
<td align="center">FoxM1 contributes to pulmonary vascular remodeling by stimulating PASMC dedifferentiation and proliferation <xref ref-type="bibr" rid="B30">Dai et al. (2018a)</xref>; <xref ref-type="bibr" rid="B32">Dai et al. (2018b)</xref>; <xref ref-type="bibr" rid="B15">Bourgeois et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">VEGF</td>
<td align="center">FoxM1 promots pyroptosis and proliferation of PASMCs <xref ref-type="bibr" rid="B177">Wu et al. (2022b)</xref>
</td>
</tr>
<tr>
<td align="center">Survivin</td>
<td align="left"/>
</tr>
<tr>
<td align="center">KIF23</td>
<td align="left"/>
</tr>
<tr>
<td align="center">NLRP3 caspase3</td>
<td align="left"/>
</tr>
<tr>
<td align="center">HMGB1</td>
<td align="left"/>
</tr>
<tr>
<td rowspan="2" align="left">KLF2</td>
<td rowspan="2" align="left">&#x2014;</td>
<td align="center">PASMC</td>
<td align="center">Missense mutation in <italic>KLF2</italic> in a family with heritable PH <xref ref-type="bibr" rid="B41">Eichstaedt et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">B cells</td>
<td align="left">A novel missense mutation in KLF2 has been identified in patients with heritable PH <xref ref-type="bibr" rid="B41">Eichstaedt et al. (2017)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">KLF5</td>
<td align="center">CyclinB1</td>
<td rowspan="2" align="center">PASMC</td>
<td rowspan="2" align="left">KLF5 promotes PASMC proliferation <xref ref-type="bibr" rid="B24">Courboulin et al. (2011)</xref>; <xref ref-type="bibr" rid="B90">Li et al. (2016b)</xref>
</td>
</tr>
<tr>
<td align="center">HIF-1&#x03B1;</td>
</tr>
<tr>
<td rowspan="3" align="left">p53</td>
<td align="center">p21</td>
<td align="center">PASMC</td>
<td align="left">p53 suppress pulmonary vascular remodeling and proliferation under hypoxic conditions. <xref ref-type="bibr" rid="B109">Mizuno et al. (2011)</xref>; <xref ref-type="bibr" rid="B111">Mouraret et al. (2013)</xref>
</td>
</tr>
<tr>
<td align="center">HIF-1&#x3b1;</td>
<td align="center">PAEC</td>
<td align="left">p53 was correlated with endothelial dysfunction in PH <xref ref-type="bibr" rid="B4">Alastalo et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="center">BMPR2</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Runx2</td>
<td align="center">HIF-1&#x3b1;</td>
<td align="center">PASMC</td>
<td align="left">Runx2 promotes PASMC proliferation and apoptosis resistance. <xref ref-type="bibr" rid="B131">Ruffenach et al. (2016)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">E2F</td>
<td align="center">CCNA2</td>
<td rowspan="2" align="center">PASMC</td>
<td rowspan="2" align="left">Pivotal regulators of cell cycle progression <xref ref-type="bibr" rid="B172">Weiss et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">CDK1</td>
</tr>
<tr>
<td align="left">EGR1</td>
<td align="center">LC3B</td>
<td align="center">PASMC</td>
<td align="left">EGR-1 promotes autophagy and alleviated PH progression under hypoxic conditions <xref ref-type="bibr" rid="B83">Lee et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left">YAP</td>
<td align="center">&#x2014;</td>
<td align="center">PASMC</td>
<td align="left">YAP aggravats hypoxia-induced autophagy and proliferation of PASMCs <xref ref-type="bibr" rid="B94">Liu et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left"/>
<td align="center">MicroRNA-130/301</td>
<td align="left"/>
<td align="left">MicroRNA-130/301 promoting collagen deposition and LOX-dependent remodeling <xref ref-type="bibr" rid="B10">Bertero et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">GLI1</td>
<td align="center">ASC</td>
<td align="center">PASMC</td>
<td align="left">GLI1 upregulats ASC by binding to its promoter and triggered pyroptosis in PASMCs <xref ref-type="bibr" rid="B60">He et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">ATF6</td>
<td align="center">Nogo-B</td>
<td align="center">PASMC</td>
<td align="left">Decreased ATF6 significantly inducing PASMC apoptosis and reversing pulmonary vascular remodeling <xref ref-type="bibr" rid="B38">Dromparis et al. (2013a)</xref>
</td>
</tr>
<tr>
<td align="left">NFATc3</td>
<td align="center">SM <italic>a</italic>-actin</td>
<td align="center">PASMC</td>
<td align="left">Inhibition of NFATc3 prevents hypoxia-induced increase in SM &#x3b1;-actin expression, arterial wall thickening <xref ref-type="bibr" rid="B54">Gonzalez Bosc et al. (2005)</xref>; <xref ref-type="bibr" rid="B34">de Frutos et al. (2007)</xref>; <xref ref-type="bibr" rid="B13">Bierer et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left">STAT5</td>
<td align="center">&#x2014;</td>
<td align="center">PASMC</td>
<td align="center">Reduced levels of STAT5 were correlated with the hypertrophy of PASMC in patients with PH <xref ref-type="bibr" rid="B182">Yang et al. (2014)</xref>
</td>
</tr>
<tr>
<td align="left">PPAR&#x3b3;</td>
<td align="center">BMPR2</td>
<td align="center">PAEC</td>
<td align="center">PPAR&#x3b3; regulates genes involved in angiogenesis, survival, and DNA repair, thus maintaining PAEC homeostasis <xref ref-type="bibr" rid="B37">Diebold et al. (2015)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="left">ZNF740</td>
<td align="center">GDF11</td>
<td rowspan="3" align="center">PAEC</td>
<td rowspan="3" align="left">ZNF740 binds to the GDF11 promoter and promoting PAEC proliferation, angiogenesis, and adhesion molecule expression <xref ref-type="bibr" rid="B185">Yu et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Smad2/3</td>
</tr>
<tr>
<td align="center">Smad1/5/8</td>
</tr>
<tr>
<td align="left">TBX4</td>
<td align="center">FGF10</td>
<td align="center">PAEC</td>
<td align="left">TBX4 is a genetic cause of PH, particularly in patients with childhood-onset of the disease <xref ref-type="bibr" rid="B184">Yoshida et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left">Sox17</td>
<td align="center">HGF c-Met</td>
<td align="center">PAEC</td>
<td align="left">Sox17 deficiency and hypoxia induce excessive EC proliferation, inflammatory activation, and long-lasting PH with high penetrance <xref ref-type="bibr" rid="B123">Park et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left">Sp1</td>
<td align="center">SHMT2</td>
<td align="center">PAEC</td>
<td align="left">Sp1 promoted PAEC proliferation and inhibited apoptosis by maintaining redox homeostasis <xref ref-type="bibr" rid="B168">Wang et al. (2022b)</xref>
</td>
</tr>
<tr>
<td align="left">FLI1</td>
<td align="center">&#x2014;</td>
<td align="center">PAEC</td>
<td align="left">Depletion of FLI1 increased EC monolayer permeability, inflammatory cell infiltration, and cytokine expression in the lungs <xref ref-type="bibr" rid="B98">Looney et al. (2017)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="left">Twist1</td>
<td align="center">Tie2</td>
<td align="center">PASMC</td>
<td align="left">Twist1 regulates VSMC proligeration and vascular remodeling <xref ref-type="bibr" rid="B102">Mammoto et al. (2016)</xref>; <xref ref-type="bibr" rid="B82">Lee et al. (2014)</xref>
</td>
</tr>
<tr>
<td align="center">PDGF</td>
<td align="center">PAEC</td>
<td align="left">Phosphorylation of Ser42 in Twist1 stimulates EndoMT of ECs through TGF-&#x3b2;/Smad signaling <xref ref-type="bibr" rid="B103">Mammoto et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">TGFBR2</td>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">GATA-6</td>
<td align="center">BMPR2</td>
<td align="center">PAEC</td>
<td align="left">GATA-6 play a critical role in ECs dysfunction in PH, and facilitated PASMC proliferation. <xref ref-type="bibr" rid="B52">Ghatnekar et al. (2013)</xref>; <xref ref-type="bibr" rid="B45">Fan et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">SNAI2</td>
<td align="center">&#x2014;</td>
<td align="center">PAEC</td>
<td align="left">Upregulated SNAI2 promoted EndoMT of PAECs <xref ref-type="bibr" rid="B64">Hopper et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="left">ZEB1</td>
<td align="center">BMPR1A</td>
<td align="center">PAEC</td>
<td align="left">ZEB1 could prevent excess EndoMT by lowering EC responses to TGF-&#x3b2; stimulation <xref ref-type="bibr" rid="B81">Lee et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left">SRF/MyoD</td>
<td align="center">&#x3b1;-SMA</td>
<td align="center">PAEC</td>
<td align="left">Cooperation of SRF and MyoD could regulate &#x3b1;-SMA transcription and PAECs transformation <xref ref-type="bibr" rid="B192">Zhang et al. (2018b)</xref>
</td>
</tr>
<tr>
<td align="left">CtBP1</td>
<td align="center">HMOX1</td>
<td align="center">adventitial fibroblasts</td>
<td align="left">Inhibiting CtBP1 decreased glycolysis and inflammatory gene expression in fibroblasts attenuated fibroblast proliferation <xref ref-type="bibr" rid="B88">Li et al. (2016a)</xref>
</td>
</tr>
<tr>
<td align="left">EGR1</td>
<td align="center">&#x2014;</td>
<td align="center">adventitial fibroblasts</td>
<td align="left">EGR-1 inhibition attenuated the proliferation of adventitial fibroblasts under hypoxic conditions <xref ref-type="bibr" rid="B51">Gerasimovskaya et al. (2002)</xref>; <xref ref-type="bibr" rid="B7">Banks et al. (2005)</xref>
</td>
</tr>
<tr>
<td align="left">Prx1</td>
<td align="center">TN-C</td>
<td align="center">ECM</td>
<td align="left">Prx1 transactivates the ECM protein tenascin-C (TN-C) gene promoter, promoting SMC proliferation <xref ref-type="bibr" rid="B72">Jones et al. (2001)</xref>
</td>
</tr>
<tr>
<td align="left">CREB</td>
<td align="center">&#x2014;</td>
<td align="center">ECM</td>
<td align="left">Loss of the transcription factor CREB promoted ECM deposition <xref ref-type="bibr" rid="B75">Klemm et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left">AP-1</td>
<td align="center">&#x2014;</td>
<td align="center">ECM</td>
<td align="left">AP-1 controls the cell proliferation, deposition, and turnover of ECM in PH <xref ref-type="bibr" rid="B166">Wagner (2010)</xref>
</td>
</tr>
<tr>
<td align="left">Fra-2/Jun-B</td>
<td align="center">Meprin &#x03B2;</td>
<td align="center">ECM</td>
<td align="left">Fra-2/Jun-B upregulates Meprin &#x03B2; and promotes extracellular matrix components such as collagen in PH <xref ref-type="bibr" rid="B12">Biasin et al. (2014)</xref>
</td>
</tr>
<tr>
<td align="left">Nrf2</td>
<td align="center">MRC1</td>
<td align="center">Macrophage</td>
<td align="left">Nrf2 mediated macrophage phenotype contributing to the development of plexiform lesions in PH <xref ref-type="bibr" rid="B138">Shao et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left">Hes1</td>
<td align="center">&#x2014;</td>
<td align="center">PAEC</td>
<td align="left">Decreased Hes1 resulting in increased EC permeability and CD45-positive immune cell infiltration <xref ref-type="bibr" rid="B170">Wang et al. (2022d)</xref>
</td>
</tr>
<tr>
<td align="left">Runx1</td>
<td align="center">p50-NF-&#x3ba;B</td>
<td align="center">macrophage</td>
<td align="left">Runx1 promotes endothelial-to-hematopoietic transformation and pulmonary macrophage recruitment which triggers the production of proinflammatory cytokines <xref ref-type="bibr" rid="B71">Jeong et al. (2022)</xref>; <xref ref-type="bibr" rid="B100">Luo et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="left">NFATc2</td>
<td align="center">&#x2014;</td>
<td align="center">T cells</td>
<td align="left">NFATc2 contributing to the inflammatory response of vascular remodeling <xref ref-type="bibr" rid="B14">Bonnet et al. (2007)</xref>
</td>
</tr>
<tr>
<td align="left">NFATc3</td>
<td align="center">COL5A1</td>
<td align="center">T cells</td>
<td align="left">NFATc3 contributed to col V-reactive Th17-mediated immune response in PH <xref ref-type="bibr" rid="B139">Sheak et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">AHR</td>
<td align="center">IL-17</td>
<td align="center">ECs bone marrow-derived cells</td>
<td align="center">AHR induced the activation of inflammation and accumulation of CD4<sup>&#x2b;</sup>IL-21<sup>&#x2b;</sup> T cells in the vascular lesions of PH rats <xref ref-type="bibr" rid="B104">Masaki et al. (2021)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2">
<title>2 Transcription factors in PASMCs that are associated with PH</title>
<p>PASMCs, located in the medial layer, are the predominant cell type in the arterial wall and play a critical role in maintaining pulmonary vascular homeostasis. The principal function of PASMCs is the regulation of pulmonary circulation and pulmonary arterial pressure. Fully differentiated PASMCs have an extremely low rate of proliferation, and highly express specific contractile proteins and cytoskeleton proteins. The contractile and cytoskeleton proteins, such as smooth muscle (SM) a-actin, SM22&#x3b1;, calponin, SM myosin heavy chain (SM MHC), and myosin light chain (MLC), make up to nearly 40% of the total PASMC protein and are required for PASMC contractile function (<xref ref-type="bibr" rid="B121">Owens, 1995</xref>). Of these proteins, SM a-actin, the most widely used marker (<xref ref-type="bibr" rid="B120">Owens et al., 2004</xref>), is the first protein expressed during SMC development (<xref ref-type="bibr" rid="B49">Galis et al., 2002</xref>). In healthy adults, venous blood flows through the right ventricle and tricuspid valve into the pulmonary artery. The robust contraction of PASMCs maintains pulmonary circulatory pressure at only a quarter of its systemic counterparts. However, as other vascular smooth muscle cells (VSMCs), PASMCs are not terminally differentiated. Following changes such as hypoxia in the pulmonary vascular microenvironment of patients with PH, PASMCs undergo a transition from a contractile phenotype to a pathological state characterized by excessive proliferation, hypertrophy, apoptosis, regulated cell death, cytokine production, and expression of growth factors (<xref ref-type="bibr" rid="B143">Sobue et al., 1999</xref>).</p>
<sec id="s2-1">
<title>2.1 Transcription factors involved in the proliferation of PASMCs</title>
<p>Pulmonary vascular remodeling is primarily caused by extensive PASMC proliferation, which leads to vascular medial thickening and luminal occlusion. PASMC contraction makes them particularly vulnerable to hypoxia and inflammation. Under these circumstances, PASMCs are comparatively prone to proliferation phenotype alteration, leading to reduced lumen diameters and increased peripheral resistance (<xref ref-type="bibr" rid="B152">Tajsic and Morrell, 2011</xref>). Chronic hypoxia-induced medium thickening can be accounted for proliferation of a specific subpopulation of SMCs within the media (<xref ref-type="bibr" rid="B146">Stenmark et al., 2006</xref>). Here, we summarize the multiple transcription factors and pathways associated with PASMC proliferation in PH (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>The transcription factors and signal pathways associated with PASMC proliferation in PH.</p>
</caption>
<graphic xlink:href="fcell-11-1132060-g001.tif"/>
</fig>
<sec id="s2-1-1">
<title>2.1.1 STAT3 transcription factor</title>
<p>Janus kinase (JAK)/signal transducer and activator of transcription (STAT) is a canonical membrane-to-nucleus pathway which can be activated by various cytokines, interferons (IFNs), and growth factors (<xref ref-type="bibr" rid="B118">O&#x27;Shea et al., 2015</xref>). Recent studies have shown that the JAK2/STAT3 pathway plays a significant role in PASMC proliferation and PH development. Hypoxia stimulates the phosphorylation of JAK2 and the activation of STAT3, resulting in the translocation of STAT3 to the nucleus. STAT3 binds to the promoter region of <italic>CCNA2</italic> (encodes cyclin A2) and transcriptionally activates cyclin A2, promoting PASMC proliferation and PH. SMC-specific JAK2 deficiency or JAK inhibitors effectively reversed the excessive, hypoxia-induced PASMC proliferation and pulmonary vascular remodeling (<xref ref-type="bibr" rid="B193">Zhang et al., 2020</xref>). Moreover, ruxolitinib, the U.S. Food and Drug Administration-approved JAK1 and JAK2 inhibitor, effectively inhibited the proliferation and migration of PASMCs in healthy individuals and patients with idiopathic pulmonary arterial hypertension (IPAH). Accordingly, ruxolitinib attenuated pulmonary vascular remodeling and the elevation of pulmonary arterial pressure both in monocrotaline (MCT)-induced PH rats and hypoxia-induced PH mice in a dose-dependent manner by blocking the JAK2/STAT3 pathway, suggesting a novel therapeutic option for PH patients (<xref ref-type="bibr" rid="B183">Yerabolu et al., 2021</xref>). Bone morphogenetic protein receptor 2 (BMPR2), a membrane protein receptor belonging to the transforming growth factor (TGF) family, mediates the binding of bone morphogenetic proteins (BMPs) that have been identified as inhibitors of PASMC proliferation. Loss-of-function mutations in BMPR2 account for approximately 75% of all PH-related abnormalities in patients with a known family history of PH (<xref ref-type="bibr" rid="B144">Soubrier et al., 2013</xref>). Downregulated BMPR2 expression has also been described in non-heritable forms of PH (<xref ref-type="bibr" rid="B5">Atkinson et al., 2002</xref>). STAT3 downregulates BMPR2 expression by activating microRNA (miR)-17/92 transcription, contributing to PH development. Inhibiting STAT3 activation by anti-cytokine therapies against IL-6 might provide a feasible alternative therapy for restoring the BMPR2 function and preventing PH development (<xref ref-type="bibr" rid="B16">Brock et al., 2009</xref>). A phase II clinical trial on the satralizumab, an anti-IL-6 receptor antibody in the treatment of PH is ongoing (NCT05679570), which may provide novel therapeutic option for PH patients. Nuclear factor of activated T cells (NFAT), a transcription factor that mediates adaptive T-cell functions, also regulates innate immunity and vascular cells in the pulmonary microenvironment (<xref ref-type="bibr" rid="B47">Fric et al., 2012</xref>). NFATc2 induces PASMC proliferation and resistance to apoptosis in the remodeling pulmonary arteries by inhibiting the expression of Kv1.5 and upregulating the expression of anti-apoptotic protein B-cell leukemia/lymphoma-2 (Bcl2) (<xref ref-type="bibr" rid="B125">Paulin et al., 2012</xref>). Interestingly, the expression of NFATc2 and the subsequent proliferation of PASMCs can be regulated by STAT3, which binds to the NFATc2 promoter region and positively regulates the NFATc2 activator, Pim-1, an oncoprotein specifically high expressed in PH (<xref ref-type="bibr" rid="B124">Paulin et al., 2011</xref>).</p>
<p>The STAT3 pathway in PASMCs is regulated by many biomolecules under hypoxic conditions, leading to proliferation-related gene activation in the nucleus. For example, platelet-derived growth factor (PDGF) is a key causative factor of PH progression that induces the hyperproliferation of PASMCs. miR-1181 inversely regulates STAT3 protein levels by interacting directly with the 3&#x2032;-UTR of STAT3 in human PASMCs, while PDGF-BB downregulates miR-1181 expression. The miR-1181/STAT3 axis functions downstream of the PDGF pathway to regulate PASMC proliferation and migration (<xref ref-type="bibr" rid="B126">Qian et al., 2018</xref>). In addition, suppressor of cytokine signaling 3 (<italic>SOCS3</italic>) has been identified as a hypoxia-inducible gene that suppresses tyrosine phosphorylation of STAT3 and transcription of the <italic>c-myc</italic> gene, inhibiting PASMC proliferation stimulated by hypoxia in a classical negative feedback loop (<xref ref-type="bibr" rid="B6">Bai et al., 2006</xref>).</p>
</sec>
<sec id="s2-1-2">
<title>2.1.2 Smad signaling</title>
<p>Another predominant transcription factor family involved in the proliferation of PASMCs is Smad. Multiple growth factors and cytokines have been reported to activate PASMC proliferation during vascular remodeling of PH (<xref ref-type="bibr" rid="B2">Akhurst and Hata, 2012</xref>). Transforming growth factor &#x3b2; (TGF-&#x3b2;) is a multifunctional cytokine that is increased in PH animal models. Different members of the Smad family have different roles in signaling. TGF-&#x3b2; receptors (TGFBRs) activate Smad2 and Smad3, whereas BMP4 receptors activate Smad1, Smad5, and Smad8. Once activated, Smad2/3 or Smad 1/5/8 form a complex with Smad4 and is translocated to the nucleus where it directly regulates the transcription of multiple target genes. These pathways have numerous functions in cell proliferation (<xref ref-type="bibr" rid="B59">Hata and Chen, 2016</xref>). TGF-&#x3b2;/Smad signaling can block cell transition from the G1 to S phase, a process known as growth arrest, by downregulating the activity of cyclin-dependent kinases (CDKs) that mediate the cell cycle (<xref ref-type="bibr" rid="B66">Huang and Huang, 2005</xref>). Under hypoxic conditions, excess TGF-&#x3b2; levels initiate cell proliferation <italic>via</italic> TGFBR-mediated activation of Smad2/3, which forms a complex with Smad4 and translocates to the nucleus to regulate multiple target genes (<xref ref-type="bibr" rid="B50">Gao et al., 2017</xref>). Osthole reportedly inhibits the TGF-&#x3b2;/Smad signaling pathway, thus decreases cyclin/CDK4 expression and induces cell cycle arrest at the G0/G1 phase. As a result, excessive PASMC proliferation and MCT-induced rat PH are prevented (<xref ref-type="bibr" rid="B186">Yue et al., 2020</xref>). Inhibitors of the DNA binding (ID) family of proteins, comprising IDs 1 to 4, are major transcriptional targets of BMP/Smad signaling and are involved in BMP/Smad-induced suppression of PASMC proliferation. Targeting the BMP/Smad pathway using the prostacyclin analogues iloprost and treprostinil inhibited the proliferation of PASMCs and prevented PH progression by enhancing Smad1/5 and ID1 signaling (<xref ref-type="bibr" rid="B180">Yang et al., 2010</xref>). Intriguingly, berberine, a natural compound that has been used in Chinese medicines for many years, increased the expression of BMPR2 and its downstream p-Smad1/5, and decreased the expression of TGF-&#x3b2; and its downstream p-Smad2/3, thus protecting against hypoxia-induced PASMC proliferation and vascular remodeling (<xref ref-type="bibr" rid="B21">Chen et al., 2019</xref>). Notably, prolonged exposure to TGF-&#x3b2; can result in loss of Smad3 (<xref ref-type="bibr" rid="B178">Yanagisawa et al., 1998</xref>). Smad3 depletion increases proliferation and migration of PASMCs, although this can be attenuated by inhibiting myocardin-related transcription factor (MRTF) (<xref ref-type="bibr" rid="B187">Zabini et al., 2018</xref>). Moreover, the clinical trials showed that inhibiting Smad2/3 signaling with sotatercept, a novel fusion protein binding activins, effectively reduced pulmonary vascular resistance in PH patients with longer-term safety and durability (<xref ref-type="bibr" rid="B69">Humbert et al., 2021</xref>; <xref ref-type="bibr" rid="B70">Humbert et al., 2023</xref>).</p>
</sec>
<sec id="s2-1-3">
<title>2.1.3 Wnt/&#x3b2;-catenin signaling pathway</title>
<p>The Wnt/&#x3b2;-catenin signaling pathway plays a prominent role in maintaining pulmonary vascular homeostasis by accelerating postinjury healing (<xref ref-type="bibr" rid="B117">Nusse and Clevers, 2017</xref>), but is also closely correlated with the pathogenesis of PH. Wnt proteins are a large family of secreted glycoproteins that signal by binding to Frizzled receptor 1 (Fzd1) and low-density lipoprotein receptor-related protein 5/6 (LRP5/6). Abnormal Wnt activation reduces the degradation of &#x03B2;-catenin by destroying the complex in the cytoplasm, resulting in &#x03B2;-catenin accumulation in the cytoplasm. Then, &#x03B2;-catenin translocates to nuclei and binds T-cell factor (TCF)/lymphoid enhancer factor (LEF) to promote the expression of downstream genes, including Cyclin D1 (<italic>CCND1</italic>), <italic>c-Myc</italic>, <italic>Axin2</italic>, and <italic>LEF1</italic> (<xref ref-type="bibr" rid="B9">Bernkopf et al., 2019</xref>). Activation of Wnt/&#x3b2;-catenin signaling also induces PASMC proliferation and vascular remodeling by inducing the expression of the downstream positive effectors Cyclin D1 and c-Myc. LF3, a small molecule, blocks the interaction between &#x03B2;-catenin and TCF4 and inhibits the downstream gene expression, thus preventing the proliferation and migration of PASMCs in rats with PH (<xref ref-type="bibr" rid="B86">Lei et al., 2021</xref>). We also recently revealed that resolvin E1 (RvE1), a pro-resolving lipid mediator, suppresses hypoxia-induced PASMC proliferation and experimental PH by inhibiting proliferative Wnt7a/&#x3b2;-catenin signaling (<xref ref-type="bibr" rid="B93">Liu et al., 2021</xref>). Thus, Wnt/&#x3b2;-catenin signaling in PASMCs may act as a therapeutic target for managing pulmonary vascular remodeling and PH.</p>
</sec>
<sec id="s2-1-4">
<title>2.1.4 Hypoxia-inducible transcription factors</title>
<p>Pulmonary hypoxic response is an evolutionarily conserved stress response triggered by reduced availability of oxygen in the alveolar (<xref ref-type="bibr" rid="B101">Luo et al., 2019</xref>). Hypoxia plays an essential role in PH and is a well-established independent cause of vascular remodeling and PH (<xref ref-type="bibr" rid="B151">Sylvester et al., 2012</xref>). Hypoxia-inducible factors (HIFs) act as key regulators of oxygen homeostasis and hypoxic adaptation in the lungs. During PH development, aberrant HIF-1&#x3b1; activation functions as a pathogenic determinant of PASMC expansion and pulmonary vascular remodeling (<xref ref-type="bibr" rid="B137">Semenza, 2012</xref>; <xref ref-type="bibr" rid="B174">Wilkins et al., 2015</xref>). A recent study showed that CD146 expression and HIF-1&#x3b1; transcription reinforce each other to physiologically promote PASMC hyperproliferation. Disruption of the CD146/HIF-1&#x3b1; crosstalk in SMCs through genetic ablation of CD146 or anti-CD146 antibodies mitigates pulmonary vascular remodeling and enhances cardiac function in different PH models, providing a proof-of-concept for anti-remodeling PH therapy (<xref ref-type="bibr" rid="B101">Luo et al., 2019</xref>). In addition, Ras-association domain family 1&#xa0;A (RASSF1A) is stabilized by hypoxia and thus bound to HIF-1&#x3b1;, preventing hydroxylation of its prolyl group, promoting nuclear translocation and subsequent transcriptional activity. This, in turn, leads to increased RASSF1A levels, resulting in a feed-forward loop and increasing proliferation and glycolysis during PH. RASSF1A ablation protects against hypoxia-induced pulmonary vascular remodeling and right ventricle hypertrophy, and this effect can be exerted in heterozygous mice (<xref ref-type="bibr" rid="B28">Dabral et al., 2019</xref>). Notch proteins are cell membrane receptors that are involved in vascular morphogenesis and function. Notch3 is a downstream target of hypoxia and is upregulated by HIF-1&#x3b1;. Compared with wild-type and Notch3<sup>&#x2b;/&#x2212;</sup> mice, Notch3<sup>&#x2212;/&#x2212;</sup> mice did not develop PH even after exposure to chronic hypoxia for 6&#xa0;weeks, and showed no muscularization of the small pulmonary arteries and arterioles, no hypertrophic remodeling, and no VSMC proliferation (<xref ref-type="bibr" rid="B91">Li et al., 2009</xref>). HIF-2&#x3b1; bound to hypoxia response elements (HRE) in secreted protein acidic and rich in cysteine (SPARC) promoter and induce SPARC expression in hypoxia-induced PASMCs. Inhibiting SPARC enhanced apoptosis, reduced the proliferation of PASMCs, and significantly improved hemodynamic and cardiac function in mice with PH (<xref ref-type="bibr" rid="B164">Veith et al., 2022</xref>).</p>
</sec>
<sec id="s2-1-5">
<title>2.1.5 FoxO1 and FoxM1</title>
<p>FoxO transcription factors are a family of transcriptional regulators containing a conserved DNA-binding domain forkhead box (<xref ref-type="bibr" rid="B1">Accili and Arden, 2004</xref>). FoxOs can act as transcriptional activators and repressors when located in the nucleus and bound to promoters that contain the FoxO consensus motif. Studies have reported that FoxOs are implicated in various cellular responses and vascular structural maintenance (<xref ref-type="bibr" rid="B119">Oellerich and Potente, 2012</xref>; <xref ref-type="bibr" rid="B42">Eijkelenboom and Burgering, 2013</xref>). FoxO1 and its downstream apoptosis-related target genes <italic>p27</italic>, B-cell lymphoma six protein (<italic>BCL6</italic>), and DNA damage-inducible protein 45 (<italic>GADD45A</italic>) are downregulated in the pulmonary vasculature of patients with IPAH as well as in rats with PH, while proliferative cyclin B1 and cyclin D1 are upregulated, indicating a hyperproliferative and apoptosis-resistant PASMC phenotype. Constitutive FoxO1 activation by adenovirus, psammaplysene (a small-molecule activator of FoxO1) or paclitaxel (an antineoplastic agent that induces FoxO1 expression and activity) efficiently reverses PASMC proliferation and PH development, indicating a potential therapeutic potential for PH intervention (<xref ref-type="bibr" rid="B135">Savai et al., 2014</xref>). A pro-proliferative TGF-&#x3b2;1-STAT3-FoxO1 axis has also been identified in hypoxia-induced PASMCs. Peroxisome proliferator-activated receptor gamma (PPAR&#x3b3;), is a nuclear receptor that functions as a transcription factor to regulate adipogenesis, metabolism, and PH development (<xref ref-type="bibr" rid="B85">Lehrke and Lazar, 2005</xref>; <xref ref-type="bibr" rid="B84">Legchenko et al., 2018</xref>). PPAR&#x3b3; inhibits TGF-&#x3b2;1-induced mitochondrial activation and PASMC proliferation, whereas the PPAR&#x3b3; agonist pioglitazone reverses PH progression by inhibiting the TGF&#x3b2;1-STAT3-FoxO1 axis in TGF-&#x3b2;1-overexpressing mice (<xref ref-type="bibr" rid="B18">Calvier et al., 2017</xref>).</p>
<p>Forkhead box M1 (FoxM1), a multifunctional transcription factor in the Forkhead family that promotes cell proliferation, angiogenesis, epithelial-mesenchymal transition, and DNA damage repair (<xref ref-type="bibr" rid="B112">Myatt and Lam, 2008</xref>; <xref ref-type="bibr" rid="B179">Yang et al., 2018</xref>), also plays a crucial role in the pathogenesis of PH (<xref ref-type="bibr" rid="B56">Gu and Liu, 2020</xref>). FoxM1 expression is elevated in PASMCs of both PH patients and animal models, stimulating PASMC dedifferentiation and proliferation. Induction of SMC-specific FoxM1 deficiency or pharmacological inhibition of FoxM1 can reverse existing pulmonary vascular remodeling and inhibit PH progression, suggesting that suppressing FoxM1 might be a promising therapeutic strategy for PH (<xref ref-type="bibr" rid="B30">Dai J. et al., 2018</xref>; <xref ref-type="bibr" rid="B32">Dai Z. Y. et al., 2018</xref>; <xref ref-type="bibr" rid="B15">Bourgeois et al., 2018</xref>). Multiple signaling pathways, including HIFs, TGF-&#x3b2;/Smad, SET domain-containing 3 (SETD3)/vascular endothelial growth factor (VEGF), survivin, cell cycle regulatory genes, and DNA damage response (DDR) networks, cross-talk with FoxM1 during PASMC proliferation and PH progression (<xref ref-type="bibr" rid="B56">Gu and Liu, 2020</xref>).</p>
</sec>
<sec id="s2-1-6">
<title>2.1.6 Kruppel-like factors (KLFs)</title>
<p>Kruppel-like factors (KLFs) belong to a family of zinc finger transcription factors and play dominant roles in the cardiovascular, immune, respiratory, digestive, and hematopoietic systems (<xref ref-type="bibr" rid="B106">McConnell and Yang, 2010</xref>). Accumulating evidence has implicated KLF signaling in PH pathogenesis. For example, a recent study identified a missense mutation in <italic>KLF2</italic> that disrupted gene function in a family with heritable PH (<xref ref-type="bibr" rid="B41">Eichstaedt et al., 2017</xref>). KLF5 expression was upregulated in both human lungs and cultured PASMCs isolated from patients with IPAH, and was correlated with disease severity. Inhibiting the STAT3 pathway abrogates KLF5 activation in hypoxia-induced PASMCs. Once activated, KLF5 promotes cyclin B1 upregulation and PASMC proliferation (<xref ref-type="bibr" rid="B24">Courboulin et al., 2011</xref>). KLF5 also acts as an upstream regulator of HIF-1&#x3b1; and promotes hypoxia-induced PASMC proliferation and migration, as well as resistance to apoptosis in a HIF-1&#x3b1;-dependent manner, providing a better understanding of PH pathogenesis (<xref ref-type="bibr" rid="B90">Li X. et al., 2016</xref>).</p>
</sec>
<sec id="s2-1-7">
<title>2.1.7 Other transcription factors</title>
<p>The growth-suppressive and pro-apoptotic transcription factor p53 plays a key role in PASMC proliferation and PH. It interacts with p21 and HIF-1&#x3b1; to suppress pulmonary vascular remodeling and proliferation under hypoxic conditions (<xref ref-type="bibr" rid="B109">Mizuno et al., 2011</xref>). Stabilizing p53 with Nutlin-3 had therapeutic effects against PH by limiting PASMC proliferation (<xref ref-type="bibr" rid="B111">Mouraret et al., 2013</xref>). Runt-related transcription factor 2 (Runx2), the key mediator of vascular calcification, is upregulated in lung, distal pulmonary arteries, and primary PASMCs isolated from PH patients, driven by miR-204 downregulation. Runx2 further triggers HIF-1&#x3b1; activation and enhances its nuclear localization, thus promoting PASMC proliferation and apoptosis resistance. Runx2 inhibition improved pulmonary hemodynamic and pulmonary vascular remodeling in rats with Sugen/hypoxia-induced PH (<xref ref-type="bibr" rid="B131">Ruffenach et al., 2016</xref>). The HIPPO signaling pathway is a key regulator of the proliferation/apoptosis balance to prevent organ overgrowth. Large tumor suppressor 1 (LATS1) is the central component of HIPPO pathway and is inactivated in PASMCs of IPAH patients, which upregulates proliferative/pro-survival signaling and promotes PASMC proliferation during PH. Pharmacological inhibition of integrin-linked kinase 1 (ILK1) upregulates LATS1, inhibits proliferation, induces apoptosis in PASMCs of individuals with PH, and reverses established pulmonary vascular remodeling and PH progression (<xref ref-type="bibr" rid="B79">Kudryashova et al., 2016</xref>). Using a congenic breeding program and comparative genomics to study two rat strains that differ in their response to chronic hypoxia, researchers identified the gene <italic>Slc39a12</italic>, which encodes the zinc transporter ZIP12, as a master regulator of hypoxia-induced pulmonary vascular remodeling. Inhibition of ZIP12 expression disrupted PASMC proliferation and attenuated PH development in rats housed under hypoxic conditions. The fundamental role of zinc transporters in mammalian pulmonary arterial homeostasis suggests a novel therapeutic target for PH management (<xref ref-type="bibr" rid="B194">Zhao et al., 2015</xref>).</p>
<p>Studies have also focused on transcription factors that are directly associated with cell cycle progression and cellular proliferation in PASMCs of individuals with PH (<xref ref-type="bibr" rid="B172">Weiss et al., 2019</xref>). For example, E2F transcription factors are pivotal regulators of cell cycle progression <italic>via</italic> the target genes <italic>CCNA2</italic> (encodes Cyclin A2) and <italic>CDK1</italic> (encodes cyclin-dependent kinase 1), which drive cells through the S phase. Inhibiting CDK using palbociclib and dinaciclib inhibits PASMC proliferation by arresting the cell cycle and interfering with the E2F signaling pathway, thus reducing pulmonary vascular remodeling in PH (<xref ref-type="bibr" rid="B172">Weiss et al., 2019</xref>).</p>
</sec>
</sec>
<sec id="s2-2">
<title>2.2 Transcription factors involved in the death of PASMCs</title>
<p>In hypoxic environments, PASMCs undergo phenotypic transformation to aberrant proliferation and apoptosis resistance. Different forms of programmed cell death (PCD) of PASMCs, including autophagy (<xref ref-type="bibr" rid="B83">Lee et al., 2011</xref>; <xref ref-type="bibr" rid="B175">Wu et al., 2019</xref>), pyroptosis (<xref ref-type="bibr" rid="B141">Shi et al., 2017</xref>) and mitochondrion-dependent apoptosis (<xref ref-type="bibr" rid="B150">Sutendra et al., 2011</xref>) have also been reported in PH (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>The transcription factors involved in the death of PASMCs.</p>
</caption>
<graphic xlink:href="fcell-11-1132060-g002.tif"/>
</fig>
<sec id="s2-2-1">
<title>2.2.1 Transcription factors associated with PASMC autophagy</title>
<p>Autophagy, represented by the conversion of microtubule-associated protein-1 light chain 3&#xa0;B (LC3B) from free form LC3B-I to phosphatidylethanolamine conjugated form LC3B-II and autophagosome formation, was increased in hypoxia-treated PASMCs and lung vasculature of patients with PH. Mechanistically, the early growth response-1 (EGR-1) transcription factor was rapidly induced to bind to the LC3B promoter upon hypoxic stimulation, and the upregulated LC3B suppressed reactive oxygen species (ROS)-dependent stabilization of HIF-1&#x3b1;. LC3B and EGR-1 deficiency reduced autophagy and aggravated PH progression under hypoxic conditions, suggesting the involvement of autophagy in pulmonary vascular remodeling (<xref ref-type="bibr" rid="B83">Lee et al., 2011</xref>). However, studies also found that autophagy contributes to BMPR2 degradation and PH development (<xref ref-type="bibr" rid="B53">Gomez-Puerto et al., 2019</xref>). Inhibition of autophagy and lysosomal BMPR2 degradation by chloroquine prevents MCT-induced PH progression in rats (<xref ref-type="bibr" rid="B97">Long et al., 2013</xref>). Similarly, liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, attenuates PASMC autophagy to ameliorate PH by inhibiting the mitochondrial fusion protein dynamin-related 1 (DRP1) and autophagy-related protein (Atg)-5/Atg-7/Beclin-1/LC3B pathway (<xref ref-type="bibr" rid="B175">Wu et al., 2019</xref>). Heat shock protein-110 (HSP110), a chaperone with anti-aggregation properties, plays a role in multiple human diseases. HSP110 expression increased significantly in the pulmonary arteries and PASMCs of mice under hypoxic conditions. Knocking down HSP110 inhibited yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) activity and TEAD4 nuclear expression, alleviating hypoxia-induced autophagy and proliferation of PASMCs, right ventricle systolic pressure, vascular wall thickening, and right ventricular hypertrophy in mice (<xref ref-type="bibr" rid="B94">Liu et al., 2022</xref>).</p>
</sec>
<sec id="s2-2-2">
<title>2.2.2 Transcription factors involved in the pyroptosis of PASMCs</title>
<p>Pyroptosis is a recently discovered and confirmed inflammatory form of cell death (<xref ref-type="bibr" rid="B35">de Gassart and Martinon, 2015</xref>). It plays a role in diverse cardiovascular disease processes (<xref ref-type="bibr" rid="B60">He et al., 2020</xref>; <xref ref-type="bibr" rid="B140">Shi et al., 2021</xref>; <xref ref-type="bibr" rid="B176">Wu Y. et al., 2022</xref>). Inflammatory caspases are pivotal for pyroptosis, and include caspase-1-mediated canonical inflammasome and caspase-4/5/11-mediated non-canonical inflammasome pathways (<xref ref-type="bibr" rid="B77">Kovacs and Miao, 2017</xref>). Caspase-1, the key effector of the inflammasome, mediates inflammation by activating the proinflammatory cytokines interleukin (IL)-18 and IL-1&#x3b2;. Impaired inflammation and SMC proliferation were observed in hypoxic caspase1<sup>&#x2212;/&#x2212;</sup> mice compared with WT controls (<xref ref-type="bibr" rid="B162">Udjus et al., 2019</xref>). Notably, glioma-associated oncogene family zinc finger 1 (GLI1), a ubiquitously distributed transcriptional activator that participates in multiple diseases, is aberrantly expressed under hypoxic conditions and is mainly distributed in PASMCs in the pulmonary arteries. GLI1 upregulates apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) that plays a crucial role in the activation of pyroptosis in PASMCs by binding to the ASC promoter region. The GLI1-specific inhibitor, GANT61, reversed pyroptotic cell death and attenuated hypoxia-induced pulmonary vascular remodeling and PH development (<xref ref-type="bibr" rid="B60">He et al., 2020</xref>). Furthermore, KIF23, the target gene of FoxM1 (<xref ref-type="bibr" rid="B92">Li et al., 2022</xref>), is a nuclear protein that regulates cytokinesis and microtubule binding. A recent study identified KIF23 as the most important gene in IPAH and pyroptosis, and its expression was markedly upregulated in PASMCs of rats with IPAH. KIF23 interacts with and regulates the expression of NLRP3, Caspase3, and HMGB1, thus promoting pyroptosis and proliferation of PASMCs. Knocking down KIF23 reduced pyroptosis in PASMCs and alleviated IPAH in rats (<xref ref-type="bibr" rid="B177">Wu Z. et al., 2022</xref>).</p>
</sec>
<sec id="s2-2-3">
<title>2.2.3 Transcription factors associated with mitochondria-dependent apoptosis of PASMCs</title>
<p>Endoplasmic reticulum (ER) stress and mitochondria-dependent apoptosis participate in PH development. Calcium from the ER, the largest cellular Ca<sup>2&#x2b;</sup> store, enters the mitochondria to promote the opening of the mitochondrial transition pore, resulting in cytochrome c release to initiate mitochondria-dependent apoptosis (<xref ref-type="bibr" rid="B189">Zamzami and Kroemer, 2001</xref>). The metabolic modulator dichloroacetate (DCA) prevents and reverses MCT-induced PH in rats by inducing mitochondria-dependent apoptosis and reversing the downregulation of Kv1.5 (<xref ref-type="bibr" rid="B107">McMurtry et al., 2004</xref>). Nogo-B, a regulator of the ER structure, is induced in PASMCs and pulmonary arteries during PH. Nogo-B disrupts the mitochondria-ER unit and decreases intramitochondrial calcium, leading to mitochondrial hyperpolarization and suppression of PASMC apoptosis (<xref ref-type="bibr" rid="B150">Sutendra et al., 2011</xref>). ER stress response involves three pathways: protein kinase R [PKR]-like ER kinase (PERK), activating transcription factor 6 (ATF6), and inositol-requiring enzyme 1&#x3b1; (IRE1&#x3b1;)-X-box binding protein 1 (XBP1). The transcription factor ATF6 is activated in hypoxic and PH PASMCs, leading to the induction of Nogo-B expression. Clinical chemical chaperones, 4-phenylbutyrate (PBA) or tauroursodeoxycholic acid, decreased ATF6 activation and induced PASMC apoptosis, significantly reducing and reversing pulmonary vascular remodeling in PH mice and rats (<xref ref-type="bibr" rid="B38">Dromparis et al., 2013a</xref>). The IRE1&#x3b1;-XBP1 pathway is also markedly upregulated in hypoxic PASMCs. 4u8c, an inhibitor of the IRE1&#x3b1;-XBP1 pathway, increased hypoxia-induced cell apoptosis by downregulating the expression of PCNA and MMP9, and activated mitochondrial apoptosis by upregulating BAX and activating caspase-9 and caspase-3 (<xref ref-type="bibr" rid="B19">Cao et al., 2019</xref>). Taken together, these observations show that targeting the key transcription factors involved in ER stress may be a novel therapeutic strategy for PH.</p>
</sec>
</sec>
<sec id="s2-3">
<title>2.3 Transcription factors associated with PASMC hypertrophy</title>
<p>PASMC hypertrophy manifests as increased cell size, appearing to be a consequence of increased intracellular protein and water content (<xref ref-type="bibr" rid="B8">Berk, 2001</xref>). NFAT, a Ca<sup>2&#x2b;</sup>-dependent transcription factor, has recently been linked to the maintenance of the smooth muscle phenotype. NFATc3 and serum response factor (SRF) bind to a region of the first intron of the SM <italic>a</italic>-actin gene, an SMC hypertrophic marker, enhancing its expression in cultured aortic smooth muscle cells (<xref ref-type="bibr" rid="B54">Gonzalez Bosc et al., 2005</xref>). NFATc3 transcriptional activity and nuclear translocation were activated in PASMCs and pulmonary arteries of both adult and neonatal mice following exposure to hypoxic conditions. Pharmacological inhibition or genetic ablation of NFATc3 prevents chronic hypoxia-induced increase in SM <italic>a</italic>-actin expression, arterial wall thickening (<xref ref-type="bibr" rid="B34">de Frutos et al., 2007</xref>), right ventricular hypertrophy and PH in mice (<xref ref-type="bibr" rid="B13">Bierer et al., 2011</xref>). Reduced levels of the transcription factor STAT5 are correlated with the hypertrophy of PASMCs in patients with PH (<xref ref-type="bibr" rid="B182">Yang et al., 2014</xref>).</p>
</sec>
</sec>
<sec id="s3">
<title>3 Transcription factors associated with pulmonary arterial endothelial cells (PAECs) during PH</title>
<p>In addition to PASMCs, endothelial cells (ECs) also play a dominant role in the initiation and progression of PH. Dysfunctional EC signaling is responsible for many of the characteristics of PH, including pulmonary inflammation, oxidative stress, vascular cell apoptosis resistance, proliferation, metabolic reprogramming, and immune cell accumulation (<xref ref-type="bibr" rid="B44">Evans et al., 2021</xref>). Genetic ablation of Egln1 (encoding prolyl-4 hydroxylase-2, PHD2) in ECs and bone marrow cells have severe PH and recapitulate many features of clinical PH in mice, including occlusive vascular remodeling and right heart failure, indicating the critical role of EC dysfunction in PH pathogenesis (<xref ref-type="bibr" rid="B31">Dai et al., 2016</xref>). Similarly, mice administered SU5416, the VEGF receptor antagonist, or rats treated with MCT develop PH that resembles human disease. In these models, endothelial apoptosis occurs in the first 3&#xa0;days of injury; however, endothelial cells become hyperproliferative and apoptosis resistant by day seven (<xref ref-type="bibr" rid="B133">Sakao et al., 2005</xref>; <xref ref-type="bibr" rid="B134">Sauler et al., 2019</xref>). Several transcription factors are associated with ECs in the pathogenesis of PH.</p>
<sec id="s3-1">
<title>3.1 Transcription factors involved in endothelial dysfunction</title>
<p>There is abundant evidence supporting the crucial involvement of HIF transcription factors in the functional alteration of PAECs other than PASMCs. Disordered proliferation and angiogenesis of PAECs are important stages in the development of PH. VEGF is a key &#x201c;end effector&#x201d; molecule in the vascular remodeling of PH that promotes angiogenesis by regulating EC proliferation, migration, and differentiation (<xref ref-type="bibr" rid="B161">Thompson and Lawrie, 2017</xref>). HIF-1&#x3b1;, a &#x201c;molecular switch,&#x201d; regulates VEGF expression. HIF-1&#x3b1; interacts with the promoter region of IL-33, resulting in the induction of IL-33 expression (<xref ref-type="bibr" rid="B148">Sun et al., 2017</xref>). Expression of IL-33 and its membrane receptor ST2 was significantly upregulated in lung tissues of mice and patients with PH. IL-33/ST2 enhances PAEC proliferation, adhesion, and angiogenesis through the HIF-1&#x3b1;/VEGFA axis, while ST2 knockout attenuates pulmonary vascular remodeling and PH development (<xref ref-type="bibr" rid="B95">Liu et al., 2018</xref>). A recent study found that HIF-2&#x3b1; activity in ECs, which is required for the initiation of hypoxia-induced PH, is activated very early following exposure to hypoxic conditions. Inflammatory factors and proliferation genes were upregulated in ECs in an HIF-2&#x3b1; (but not HIF-1&#x3b1;)-dependent manner in response to acute hypoxia. A small-molecule inhibitor of HIF-2&#x3b1;, PT2567, or EC HIF-2&#x3b1; knockout significantly reduced the progression of hypoxia-induced PH in adult rats (<xref ref-type="bibr" rid="B65">Hu et al., 2019</xref>). Likewise, EC deletion of arginase-1, another downstream target of HIF-2&#x3b1;, attenuated many of the pathophysiological symptoms associated with hypoxic PH. Chronic hypoxia enhanced HIF-2&#x3b1; stability, increasing arginase expression and dysregulating normal vascular NO homeostasis (<xref ref-type="bibr" rid="B26">Cowburn et al., 2016</xref>). In addition, HIF-2&#x3b1; interacted with p53 to accelerate EC apoptosis under hypoxia, resulting in the dysfunction of pulmonary arterial endothelium (<xref ref-type="bibr" rid="B171">Wang et al., 2019</xref>). Of note, Nutlin3a-mediated p53 induction could inhibit PASMC proliferation and PH development (<xref ref-type="bibr" rid="B111">Mouraret et al., 2013</xref>), but it would also enhance PAEC apoptosis and exert a potentially pathogenic effect on PH. Thus, a combination of the p53 agonist Nutlin3a and the HIF-2&#x3b1; antagonist PT2385 confers greater therapeutic efficacy against PH, than monotherapy with either agent alone (<xref ref-type="bibr" rid="B195">Zheng et al., 2022</xref>).</p>
<p>Numerous studies have linked PAEC dysfunction in PH to mutations or dysfunctions in BMPR2 (<xref ref-type="bibr" rid="B80">Lane et al., 2000</xref>; <xref ref-type="bibr" rid="B158">Teichert-Kuliszewska et al., 2006</xref>). Specifically, two transcription factors, PPAR&#x3b3; and tumor suppressor p53, mediate gene regulation downstream of BMPR2 in PAECs and are correlated with endothelial dysfunction in PH (<xref ref-type="bibr" rid="B4">Alastalo et al., 2011</xref>; <xref ref-type="bibr" rid="B37">Diebold et al., 2015</xref>). In addition, BMPR2 signaling is particularly prominent in maintaining DNA integrity in PAECs under hypoxic conditions (<xref ref-type="bibr" rid="B89">Li et al., 2014</xref>). Interestingly, PPAR&#x3b3; and p53 form a DNA damage-dependent transcription factor complex that regulates genes involved in angiogenesis, survival, and DNA repair, thus maintaining PAEC homeostasis. Conditional BMPR2 deletion in ECs promoted DNA damage and PAEC apoptosis and impaired the reversal of hypoxia-associated PH, similar to mice with PPAR&#x3b3; deletion in ECs (<xref ref-type="bibr" rid="B4">Alastalo et al., 2011</xref>; <xref ref-type="bibr" rid="B37">Diebold et al., 2015</xref>). However, stabilization of p53 with Nutlin-3 could rescueimpaired PPAR&#x3b3;-p53 complex formation and reversed PH in EC-BMPR2 deficient mice (<xref ref-type="bibr" rid="B61">Hennigs et al., 2021</xref>). Hypoxia also decreased PPAR&#x3b3; and miR-98 expression, increasing the levels of endothelin-1 (ET-1), which stimulates PAEC proliferation and contributes to pulmonary vascular remodeling and PH. Activation of PPAR&#x3b3; using rosiglitazone attenuated PAEC proliferation and hypoxia-induced PH by restoring miR-98 levels (<xref ref-type="bibr" rid="B73">Kang et al., 2016</xref>). Growth differentiation factor 11 (GDF11), also known as BMP11, is a member of the BMP/TGF-&#x3b2; superfamily. During PH, the transcription factor zinc finger protein 740 (ZNF740) activates GDF11 expression, thus activating Smad2/3 and Smad1/5/8 signaling in PAECs and promoting PAEC proliferation and angiogenesis. EC-specific GDF11 knockout or ZNF740 inhibition attenuates pulmonary vascular remodeling and PH (<xref ref-type="bibr" rid="B185">Yu et al., 2018</xref>). Mediator complex subunit 1 (MED1) is a key transcriptional coactivator and KLF4 is a master transcription factor in the endothelium. MED1 acts synergistically with KLF4 to transactivate BMPR2, ERG, and TGFBR2 <italic>via</italic> chromatin remodeling and enhancer-promoter interactions in PAECs. MED1 levels were decreased in the lung tissue and PAECs of patients and mice with PH, while MED1 overexpression mitigated the PH phenotype in rodents (<xref ref-type="bibr" rid="B167">Wang C. et al., 2022</xref>).</p>
<p>Notch signaling has been implicated in vascular development, homeostasis, and injury responses. The expression and transcriptional activity of Notch1 in PAECs increases under hypoxic conditions. Inhibiting Notch1 increased p21 expression and the Bax/Bcl-2 ratio, thus significantly reducing PAECsproliferation and apoptosis resistance during PH (<xref ref-type="bibr" rid="B29">Dabral et al., 2016</xref>). Notch2 promotes endothelial apoptosis and its expression was attenuated in PAECs exposed to vasoactive stimuli, including hypoxia, TGF-&#x3b2;, and ET-1. Decreased levels of Notch2 increased E2F1 binding to the Notch1 promoter and upregulated Notch1 expression, promoting PAEC proliferation and resistance to apoptosis and resulting in endothelial dysfunction and subsequent PH-associated vascular remodeling (<xref ref-type="bibr" rid="B132">Sahoo et al., 2021</xref>).</p>
<p>TBX4<italic>,</italic> a member of the TBX family of proteins containing a T-box DNA-binding domain, is a transcription factor crucial for lung development (<xref ref-type="bibr" rid="B122">Papaioannou, 2014</xref>). Genetic researches have reported that <italic>TBX4,</italic> located on chromosome 17q23.2, is a genetic cause of PH, particularly in patients with childhood-onset of the disease (<xref ref-type="bibr" rid="B116">Nimmakayalu et al., 2011</xref>; <xref ref-type="bibr" rid="B74">Kerstjens-Frederikse et al., 2013</xref>). Fibroblast growth factor 10 (FGF10) is essential for fetal lung development. <italic>TBX4</italic> directly regulates FGF10 through a consensus T-box binding site, whereas the TBX4 variants (<italic>p</italic>.L257&#xa0;T&#xa0;fs&#x2a;129 and <italic>p</italic>. R126C) do not activate FGF10 and fail to induce maturation of the pulmonary vascular endothelium, a potential cause of PH (<xref ref-type="bibr" rid="B184">Yoshida et al., 2022</xref>).</p>
<p>Large-scale genomic studies have suggested that SRY-related HMG-box17 (Sox17), an endothelial-specific transcription factor that regulates EC and vascular homeostasis, is a putative causal gene for PH (<xref ref-type="bibr" rid="B55">Graf et al., 2018</xref>; <xref ref-type="bibr" rid="B63">Hiraide et al., 2018</xref>; <xref ref-type="bibr" rid="B196">Zhu et al., 2018</xref>; <xref ref-type="bibr" rid="B130">Rhodes et al., 2019</xref>). Indeed, Sox17 deficiency and hypoxia induce excessive EC proliferation, inflammatory activation, and long-lasting PH with high penetrance. Mechanistically, Sox17 deficiency activates hepatocyte growth factor (HGF) and its receptor c-Met, which promotes cell growth. Sox17 dysfunction and reactive upregulation of HGF/c-Met signaling may act as novel druggable targets for PH treatment (<xref ref-type="bibr" rid="B123">Park et al., 2022</xref>).</p>
<p>Dickkopf 1 (DKK1), a secretory glycoprotein, plays a pathologic role in the development of PH. Increased DKK1 levels in PAECs during PH activate the transcription of Serine Hydroxymethyltransferase 2 (SHMT2) <italic>via</italic> the transcription factor specificity protein 1 (Sp1), promoting PAEC proliferation and inhibiting apoptosis by maintaining redox homeostasis. Endothelium-specific knockdown of DKK1 or DKK1 neutralizing antibodies significantly ameliorate PH progression (<xref ref-type="bibr" rid="B168">Wang Q. Q. et al., 2022</xref>).</p>
<p>The E-twenty-six (ETS) family of transcription factors is a prominent regulator of the gene network maintaining endothelial homeostasis. The expression of Friend leukemia integration one transcription factor (FLI1), a ETS family member, and its closest homolog, ETS-related gene (ERG), were significantly downregulated in ECs in lungs of patients and mice with PH. Depletion of ERG or FLI1 increased EC monolayer permeability, inflammatory cell infiltration, and cytokine expression in the lungs. Thus, the loss of ERG or FLI1 in ECs may contribute to the pathogenesis of PH through induction of inflammation (<xref ref-type="bibr" rid="B98">Looney et al., 2017</xref>).</p>
</sec>
<sec id="s3-2">
<title>3.2 Transcription factors associated with endothelial-to-mesenchymal transition (EndoMT)</title>
<p>Endothelial-to-mesenchymal transition (EndoMT) is a biological process through which ECs acquire a mesenchymal or myofibroblastic phenotype. During this process, ECs lose their cell-cell junctions and gain migratory and invasive abilities that enable them to reach surrounding tissues. During migration, the cells express reduced levels of specific endothelial markers such as CD31 and VE-cadherin, and progressively express mesenchymal or myofibroblastic markers, including <italic>a</italic>-SMA and vimentin (<xref ref-type="bibr" rid="B48">Frid et al., 2002</xref>). Cells with a mixed mesenchymal/endothelial phenotype are present in the intimal and plexiform lesions of PH lungs, and EndoMT is a critical mechanism of pulmonary vascular remodeling responsible for PH both in human and experimental PH animals (<xref ref-type="bibr" rid="B128">Ranchoux et al., 2015</xref>). Transcriptional factors such as Twist-1, HIFs, SNAIs, and high-mobility group AT-hook 1 (HMGA1) in PAECs have been revealed as the master factors initiating EndoMT during PH pathology.</p>
<p>The transcription factor Twist1 controls the expression of various angiogenic factors and receptors such as Tie2 (<xref ref-type="bibr" rid="B102">Mammoto et al., 2016</xref>) and PDGF (<xref ref-type="bibr" rid="B82">Lee et al., 2014</xref>), which control VSMC proliferation and vascular remodeling. Twist1 also cross-talks with HIF-1&#x3b1; (<xref ref-type="bibr" rid="B181">Yang and Wu, 2008</xref>), Wnt (<xref ref-type="bibr" rid="B173">West et al., 2014</xref>), and TGF-&#x3b2; (<xref ref-type="bibr" rid="B27">Cufi et al., 2010</xref>), which mediate the pathogenesis of PH. Twist1 expression is enhanced in the lungs of PH patients. Twist1 binds to the TGFBR2 promoter region to promote its transcriptional activity. Phosphorylation of Ser42 in Twist1 stimulates EndoMT of ECs through TGF-&#x3b2;/Smad signaling, while knocking down Twist1 attenuates hypoxia-induced pulmonary arterial remodeling and PH progression in mice (<xref ref-type="bibr" rid="B103">Mammoto et al., 2018</xref>). HIF-1&#x3b1; is also essential for hypoxia-induced EndoMT. Interestingly, HIF-1&#x3b1; was found to bind to the <italic>Twist1</italic> promoter, thus activating <italic>Twist1</italic> transcription and regulating EndoMT in hypoxia-induced ECs (<xref ref-type="bibr" rid="B191">Zhang B. et al., 2018</xref>). GATA-6, a member of the GATA family of zinc-finger transcription factors, plays a critical role in EC dysfunction in PH (<xref ref-type="bibr" rid="B52">Ghatnekar et al., 2013</xref>). BMPR2 has been recognized as a novel downstream target of GATA-6, which directly binds to the BMPR2 promoter. Twist1 promotes the ubiquitination-proteasomal degradation of GATA-6, thus repressing BMPR2 transcription and facilitating PASMC proliferation and migration (<xref ref-type="bibr" rid="B45">Fan et al., 2020</xref>). Taken together, these findings show that inhibiting Twist1 may constitute a new therapeutic strategy for PH.</p>
<p>The SNAI zinc-finger transcription factors, including SNAI1, SNAI2, and SNAI3 (also known as SNAIL, SLUG, and SMUC, respectively), has been reported to play a central role in the progression of EndoMT (<xref ref-type="bibr" rid="B76">Kokudo et al., 2008</xref>). Loss of BMPR2 in PAECs leads to increased HMGA1 expression, which upregulates SNAI2 and promotes EndoMT of PAECs (<xref ref-type="bibr" rid="B64">Hopper et al., 2016</xref>). HIF-2&#x3b1; transcriptionally upregulates SNAI1 and SNAI2, subsequently triggering EndoMT in ECs of patients with PH (<xref ref-type="bibr" rid="B96">Liu et al., 2011</xref>; <xref ref-type="bibr" rid="B156">Tang et al., 2018</xref>). Furthermore, HIF-2&#x3b1; potently increases EC nicotinamide phosphoribosyl transferase (NAMPT) promoter activity and promotes EndoMT. Inhibiting NAMPT significantly reduced MCT-induced vascular remodeling, NF-&#x3ba;B activation, and PH development, providing a novel and attractive therapeutic target for PH vascular remodeling (<xref ref-type="bibr" rid="B149">Sun et al., 2020</xref>).</p>
<p>In addition to BMPR2, BMPR1 is also important for maintaining endothelial identity and preventing excess EndoMT. The transcription factor ZEB1 is the primary target of BMPR1A. Following BMPR1A activation, ID2 physically interacts with and sequesters ZEB1 to inhibit the transcription of TGFBR2, in turn lowering EC responses to TGF-&#x3b2; stimulation and preventing excess EndoMT. BMPR1A-ID2/ZEB1-TGFBR2 signaling may serve as a promising therapeutic target for PH and other EndoMT-related vascular disorders (<xref ref-type="bibr" rid="B81">Lee et al., 2022</xref>).</p>
<p>The expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1&#x3b1;) was recently shown to be suppressed in PAECs of patients with PH as well as in hypoxia-induced PH mice. PGC-1&#x3b1; overexpression rescued the expression of endothelial nitric oxide synthase (eNOS) and blocked EndoMT of PAECs during PH (<xref ref-type="bibr" rid="B17">Cai and Chen, 2022</xref>). In addition, Galectin-3, a member of the <italic>&#xdf;</italic>-galactoside-binding gene family, facilitated the cooperation between transcription factor SRF and myogenic differentiation 1 (MyoD), regulating <italic>a</italic>-SMA transcription and PAEC transformation (<xref ref-type="bibr" rid="B192">Zhang L. et al., 2018</xref>).</p>
</sec>
</sec>
<sec id="s4">
<title>4 Transcription factors that are activated in fibroblasts and extracellular matrix (ECM) during PH</title>
<p>The extracellular matrix (ECM) comprises all extracellular constituents that are crucial for tissue structure, function, and intercellular communication. The ECM is necessary for maintaining tissue homeostasis under both physiological and pathophysiological conditions, and too little or too much ECM production can result in severe dysfunction. Alterations in the vascular ECM are increasingly being recognized as key drivers of PH. Fibroblasts are the predominant producers of ECM (<xref ref-type="bibr" rid="B36">DeLeon-Pennell et al., 2020</xref>). Activated fibroblasts are prone to secreting extra ECM, which interferes with pulmonary vascular homeostasis under hypoxic environments in lung vasculature of individuals with PH. Robust proliferation of fibroblasts and accumulation of macrophages were observed in the pulmonary artery adventitia in the early stage of PH (<xref ref-type="bibr" rid="B33">Das et al., 2008</xref>; <xref ref-type="bibr" rid="B87">Li et al., 2011</xref>; <xref ref-type="bibr" rid="B43">El Kasmi et al., 2014</xref>). Metabolic reprogramming has been suggested to contribute to the aberrant phenotype of fibroblasts in PH. C-terminal binding protein 1 (CtBP1), the NADH-sensitive transcriptional corepressor, is a potential sensor of the cellular metabolic state that modulates the cell phenotype (<xref ref-type="bibr" rid="B22">Chinnadurai, 2009</xref>). The anti-inflammatory gene, <italic>HMOX1</italic>, is a direct target of CtBP1. Inhibiting CtBP1 or NADH decreased glycolysis and inflammatory gene expression in fibroblasts attenuated fibroblast proliferation and suppressed macrophage accumulation in patients with PH (<xref ref-type="bibr" rid="B88">Li M. et al., 2016</xref>). Cultured pulmonary artery fibroblasts showed increased expression and DNA-binding activity of the EGR-1 transcription factor in response to hypoxia. Directly inhibiting EGR-1 attenuated the proliferation of adventitial fibroblasts under hypoxic conditions (<xref ref-type="bibr" rid="B51">Gerasimovskaya et al., 2002</xref>; <xref ref-type="bibr" rid="B7">Banks et al., 2005</xref>).</p>
<p>ECM remodeling and pulmonary vascular stiffness occur early in the PH process, even before the increase of intimal and medial thickness and pulmonary arterial pressure, suggesting a causal role rather than a consequence of ECM in pulmonary vascular remodeling (<xref ref-type="bibr" rid="B159">Thenappan et al., 2018a</xref>). Pharmacological inhibition of vascular ECM constituents such as serine elastase, lysyl oxidase (LOX), and periostin, can reverse pulmonary vascular remodeling and ameliorate PH development (<xref ref-type="bibr" rid="B25">Cowan et al., 2000</xref>; <xref ref-type="bibr" rid="B114">Nave et al., 2014</xref>; <xref ref-type="bibr" rid="B115">Nie et al., 2020</xref>). Indeed, ECM remodeling and stiffness may trigger the proliferation of adventitial fibroblasts, ECs, and VSMCs through mechanoactivation of various transcription factors and signaling pathways. The transcriptional coactivators YAP and TAZ are important for mechanotransduction, which converts extracellular mechanical cues into intracellular signals (<xref ref-type="bibr" rid="B40">Dupont et al., 2011</xref>). It has recently been proposed that YAP and TAZ activation by ECM stiffening is a molecular driver of PH (<xref ref-type="bibr" rid="B10">Bertero et al., 2015</xref>; <xref ref-type="bibr" rid="B11">Bertero et al., 2016</xref>). ECM stiffening induces the microRNA-130/301 family by activating YAP/TAZ. MicroRNA-130/301 controls the PPAR&#x3b3;-ApoE-LDL receptor-related protein 8 (LRP8) axis, promoting collagen deposition and LOX-dependent remodeling. Therapeutic targeting of the downstream ApoE or LOX suppresses YAP/TAZ-miR-130/301 circuit and ameliorates ECM remodeling and PH (<xref ref-type="bibr" rid="B10">Bertero et al., 2015</xref>). Furthermore, ECM stiffening promoted vascular cell growth and migration through YAP/TAZ-dependent glutaminolysis and anaplerosis. The finding links mechanical stimuli to dysregulated vascular metabolism and identifies potential metabolic drug targets for developing PH therapeutics (<xref ref-type="bibr" rid="B11">Bertero et al., 2016</xref>). Expression of the homeobox transcription factor Prx1 is upregulated during PH and transactivates the ECM protein tenascin-C (TN-C) gene promoter, promoting SMC proliferation and PH progress (<xref ref-type="bibr" rid="B72">Jones et al., 2001</xref>). Mammalian Ste20-like kinases (MSTs) 1/2 are members of the HIPPO pathway that act as growth suppressors of proliferative diseases in adults. However, in contrast to canonical antiproliferative/proapoptotic roles, MST1/2 acts as a pro-proliferative/prosurvival molecule in human pulmonary arterial adventitial fibroblasts by downregulating FoxO3 and promoting established pulmonary vascular remodeling in PH mice (<xref ref-type="bibr" rid="B78">Kudryashova et al., 2022</xref>).</p>
<p>In addition, oxidative stress contributes to pulmonary arterial remodeling by stimulating the loss of the transcription factor CREB and promoting SMC growth and ECM deposition. The oxidant scavenger Tempol effectively attenuates chronic hypoxia-induced CREB loss, excessive elastin/matrix production, and pulmonary arterial remodeling (<xref ref-type="bibr" rid="B75">Klemm et al., 2011</xref>). The activator protein-1 (AP-1) complex, a dimeric transcription factor composed of Fos (c-Fos, Fra-1, Fra-2, FosB) and Jun (c-Jun, Jun-B, Jun-D) proteins has been implicated in the control of cell proliferation, deposition, and turnover of ECM (<xref ref-type="bibr" rid="B166">Wagner, 2010</xref>). Fra-2 transgenic mice are novel models of PH associated with systemic sclerosis (<xref ref-type="bibr" rid="B105">Maurer et al., 2012</xref>). Mechanistically, the Fra-2/Jun-B complex binds to the meprin &#x03B2; promoter, leading to upregulated expression. Meprin &#x03B2; promotes vascular remodeling in PH by acting on extracellular matrix components such as collagen (<xref ref-type="bibr" rid="B12">Biasin et al., 2014</xref>).</p>
</sec>
<sec id="s5">
<title>5 Transcription factors activated in immune cells during PH</title>
<p>In recent years, greater attention has been paid to the frequently observed perivascular inflammation in PH patients. Inflammatory and autoimmune processes are increasingly being recognized as major pathogenic factors of pulmonary arterial remodeling. Pulmonary vascular lesions in patients and animals with PH are characterized by varying degrees of perivascular inflammatory infiltrates, including macrophages, T- and B-lymphocytes, dendritic cells (DCs), and mast cells (<xref ref-type="bibr" rid="B136">Savai et al., 2012</xref>). In addition to increased perivascular immune cell accumulation and intravascular infiltration, high levels of various cytokines and chemokines, including IL-1&#x3b2;, IL-6, IL-8, monocyte chemoattractant protein 1 (MCP-1), chemokine ligand 5 (CCL5), and tumor necrosis factor (TNF)-&#x3b1;, have been identified in PH animals and patients. These cytokines and chemokines are correlated with poor clinical outcomes in patients with PH and may serve as potential biomarkers of PH progression (<xref ref-type="bibr" rid="B127">Rabinovitch et al., 2014</xref>). Concomitantly, vascular cells, including ECs, PASMCs, and fibroblasts, may also change their phenotypes, resulting in enhanced capacity to stage inflammatory responses and increased secretion of cytokines and chemokines. Transcription factors play prominent roles in immune cells and inflammatory responses during PH.</p>
<sec id="s5-1">
<title>5.1 Transcription factors in macrophages</title>
<p>Macrophages are the most abundant inflammatory cells in lung tissue (<xref ref-type="bibr" rid="B129">Reyfman et al., 2019</xref>). Early and persistent accumulation of macrophages has been observed in perivascular lesions in PH patients as well as animals (<xref ref-type="bibr" rid="B165">Vergadi et al., 2011</xref>). Altered macrophage polarization can induce experimental PH (<xref ref-type="bibr" rid="B190">Zawia et al., 2021</xref>). Interventions targeting macrophages, for example macrophage depletion, have confirmed their causal roles in PH and pulmonary vascular remodeling (<xref ref-type="bibr" rid="B153">Talati et al., 2016</xref>; <xref ref-type="bibr" rid="B188">Zaloudikova et al., 2016</xref>).</p>
<p>Adventitial fibroblasts derived from hypertensive pulmonary arteries activate macrophages through paracrine IL-6 and STAT3, HIF-1&#x3b1;, and C/EBP&#x3b2; signaling to drive the expression of genes involved in inflammatory response, tissue remodeling, and PH. Targeting IL-6 signaling in macrophages by completely inhibiting C/EBP&#x3b2; or HIF-1&#x3b1; or by partially inhibiting STAT3 presents therapeutic value for treating PH (<xref ref-type="bibr" rid="B43">El Kasmi et al., 2014</xref>). Right ventricular function is considered a major determinant of cardiac capacity and survival of patients with PH. The NLRP3 inflammasome pathway within the right ventricular macrophages was activated in two robust preclinical PH models and in patients with PH. Blocking the IL-6/STAT3 pathway suppressed macrophage accumulation and NLRP3 inflammasome activation, thus improving cardiac function in PH rats (<xref ref-type="bibr" rid="B3">Al-Qazazi et al., 2022</xref>).</p>
<p>Nuclear factor erythroid 2-related factor 2 (Nrf2), a stress-responsive transcription factor, binds to the promoter of the macrophage lineage marker, mannose receptor C-type 1 (MRC1), to trigger its expression. Thus, Nrf2 mediates bone marrow-derived early progenitor endothelial cell (eEPC) transformation to the macrophage phenotype, contributing to the development of plexiform lesions in PH (<xref ref-type="bibr" rid="B138">Shao et al., 2022</xref>). Impaired Notch1 cleavage in PAECs decreases the expression of the downstream transcription factor Hes1, resulting in increased EC permeability and CD45-positive immune cell infiltration in PH mouse models (<xref ref-type="bibr" rid="B170">Wang S. M. et al., 2022</xref>). Direct binding of the transcription factor Runx1 to p50-NF-&#x3ba;B in macrophages triggers the production of proinflammatory cytokines (<xref ref-type="bibr" rid="B100">Luo et al., 2016</xref>). Furthermore, Runx1 promotes endothelial-to-hematopoietic transformation and pulmonary macrophage recruitment and activation during PH progression. Genetic ablation of Runx1 in adult endothelium or in myeloid lineage cells protected mice against developing PH and reversed established PH and improved vascular remodeling in rats (<xref ref-type="bibr" rid="B71">Jeong et al., 2022</xref>).</p>
</sec>
<sec id="s5-2">
<title>5.2 Transcription factors in T cells</title>
<p>T cell-deficient athymic rats developed particularly severe PH (<xref ref-type="bibr" rid="B108">Miyata et al., 2000</xref>; <xref ref-type="bibr" rid="B157">Taraseviciene-Stewart et al., 2007</xref>), whereas immune reconstitution prevented early accumulation of macrophages and B cells, attenuated pulmonary endothelial apoptosis, and upregulated BMPR2 expression, thus preventing experimental PH (<xref ref-type="bibr" rid="B155">Tamosiuniene et al., 2011</xref>). Similarly, regulatory T cell (Treg) treatment significantly decreased pro-inflammatory cytokine expression and enhanced the expression of vasoprotective proteins such as cyclooxygenase 2 (COX-2), programmed death ligand 1 (PDL-1), and heme oxygenase 1 (HO-1), thus protecting against PH development (<xref ref-type="bibr" rid="B23">Chu et al., 2015</xref>; <xref ref-type="bibr" rid="B154">Tamosiuniene et al., 2018</xref>). The fact that inflammation precedes vascular remodeling suggests a causal role of altered immunity in PH progression.</p>
<p>NFAT, a Ca2<sup>&#x2b;</sup>/calcineurin-sensitive transcription factor, is a key T cell activator and plays a central role in the pathogenesis of PH. NFATc2 is activated in the pulmonary arteries and in circulating CD3-positive T lymphocytes, contributing to the inflammatory response of vascular remodeling. NFAT inhibition reversed the effects of established PH in rats (<xref ref-type="bibr" rid="B14">Bonnet et al., 2007</xref>). NF-&#x3ba;B is activated in the pulmonary arterial lesions of PH patients and rats. Inhibiting NF-&#x3ba;B using pyrrolidine dithiocarbamate (PDTC) mitigated and prevented pulmonary arterial obliteration in rats by increasing perivascular CD4<sup>&#x2b;</sup> T cells (particularly Tregs) and reducing perivascular CD8<sup>&#x2b;</sup> T lymphocytes and CD45RA<sup>&#x2b;</sup> B lymphocytes (<xref ref-type="bibr" rid="B46">Farkas et al., 2014</xref>). The protective role of sulfasalazine, an NF-&#x3ba;B inhibitor, is being verified by a phase I clinical trial (NCT04528056).</p>
<p>The T helper 2 (Th2) cell immune response is also implicated in pulmonary vascular remodeling during PH progression. The expression of a chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) was upregulated in circulating CD3<sup>&#x2b;</sup>CD4<sup>&#x2b;</sup> T cells in PH patients and animals. CRTH2 promoted Th2 cell activation, inducing PASMC proliferation through STAT6 activation. Targeting the CRTH2-mediated Th2 response provides a potential therapeutic strategy for PH (<xref ref-type="bibr" rid="B20">Chen et al., 2018</xref>). Chronic hypoxia-induced PH partly results from T helper 17 (Th17)-mediated perivascular inflammation. NFATc3 is an important transcription factor for chronic hypoxia-induced PH in adult mice. Study finds that NFATc3 directly regulates the expression of the lung self-antigen <italic>COL5A1</italic>, the gene encoding the &#x3b1;1-helix of collagen type V (col V), contributing to col V-reactive Th17-mediated immune response in PH (<xref ref-type="bibr" rid="B139">Sheak et al., 2020</xref>). The aryl hydrocarbon receptor (AHR), a nuclear receptor/transcription factor, mediates multiple immune diseases by regulating inflammatory signals, including cytokine and chemokine signals (<xref ref-type="bibr" rid="B147">Stockinger et al., 2014</xref>). AHR promotes IL-17-producing Th17 differentiation (<xref ref-type="bibr" rid="B113">Nakahama et al., 2013</xref>). The IL-6/Th17/IL-21 axis plays a prominent role in a hypoxia-induced PH in mouse models by promoting M2 macrophage polarization (<xref ref-type="bibr" rid="B57">Hashimoto-Kataoka et al., 2015</xref>). Moreover, AHR in both ECs and bone marrow-derived cells induced the activation of inflammation and accumulation of CD4<sup>&#x2b;</sup>IL-21<sup>&#x2b;</sup> T cells in the vascular lesions of PH rats in the advanced stages. The AHR signaling pathway may be a novel therapeutic target for PH, and AHR agonistic activity in the serum is a PH biomarker (<xref ref-type="bibr" rid="B104">Masaki et al., 2021</xref>).</p>
</sec>
<sec id="s5-3">
<title>5.3 Transcription factors in B cells</title>
<p>B cells play a vital role in lung hemostasis. Pulmonary injury, together with enhanced B-cell activation, is sufficient for inducing PH symptoms in mice, and adaptive immune activation contributes to IPAH induction or progression (<xref ref-type="bibr" rid="B62">Heukels et al., 2021</xref>). Simultaneously, IPAH patients have a distinct RNA expression profile of peripheral blood B-lymphocyte compared with that of healthy controls, with several genes being clearly upregulated (<xref ref-type="bibr" rid="B163">Ulrich et al., 2008</xref>). Elimination of B lymphocytes with anti-CD20 antibody prevented the increase of HIF-1&#x3b1; and VEGF and reduced mean pulmonary arterial pressure in mice with PH (<xref ref-type="bibr" rid="B110">Mizuno et al., 2012</xref>). A novel missense mutation in the transcription factor KLF2, which has been described as a recurrent somatic mutation in B-cell lymphoma, has also been identified in patients with heritable PH (<xref ref-type="bibr" rid="B41">Eichstaedt et al., 2017</xref>). These findings will improve our understanding of the multifunctional roles of B cells in PH.</p>
</sec>
</sec>
<sec id="s6">
<title>6 Conclusion and perspectives</title>
<p>Pulmonary vascular remodeling is characterized by medial hypertrophy/hyperplasia, intimal and adventitial fibrosis, plexiform lesions, and perivascular infiltration of immune cells (<xref ref-type="bibr" rid="B67">Humbert et al., 2019</xref>). It is well established that complex interactions among cells and signaling pathways are involved in the development of pulmonary vascular remodeling. The original concept that PH is largely caused by vasoconstriction has expanded over the last few decades. However, it is now accepted that therapeutic strategies are supposed to address not only vasodilation, but also pulmonary vascular remodeling, by inhibiting proliferative mechanisms to reduce PH mortality. Transcription factors and associated signaling pathways play predominant roles in pulmonary vascular remodeling and PH pathogenesis (<xref ref-type="fig" rid="F3">Figure 3</xref>). Approaches targeting single cytokines, growth factors, or receptor tyrosine kinases may generate limited efficacy because of the complicated stimuli implicated in pulmonary vascular remodeling. One promising strategy is to target the prominent downstream effector molecules such as transcription factors that integrate various signal pathways. Although multiple transcription factors and their associated therapeutic roles in PH have been suggested, further in-depth and comprehensive research in this field is needed to identify new opportunities for strategic PH intervention and drug development. Moreover, further investigations are required to evaluate the clinical applicability of PH therapies targeting transcription factors.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Summary of the involvement of transcription factors in the development of pulmonary vascular remodeling during PH.</p>
</caption>
<graphic xlink:href="fcell-11-1132060-g003.tif"/>
</fig>
</sec>
</body>
<back>
<sec id="s7">
<title>Author contributions</title>
<p>LY, NW, and GL designed the research and associated with the project. FG and GL drew the figure. LY, NW, XW, LF, and GL wrote the manuscript.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This work was supported by the National Natural Science Foundation of China (82270284, 82200532), Guangdong Department of Science and Technology Grant (2019A1515010672) and Fundamental Research Funds for the Central Universities (JUSRP123065, JUSRP123071).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Accili</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Arden</surname>
<given-names>K. C.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>FoxOs at the crossroads of cellular metabolism, differentiation, and transformation</article-title>. <source>Cell</source> <volume>117</volume>, <fpage>421</fpage>&#x2013;<lpage>426</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(04)00452-0</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akhurst</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Hata</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Targeting the TGF&#x3b2; signalling pathway in disease</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>11</volume>, <fpage>790</fpage>&#x2013;<lpage>811</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3810</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Qazazi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lima</surname>
<given-names>P. D. A.</given-names>
</name>
<name>
<surname>Prisco</surname>
<given-names>S. Z.</given-names>
</name>
<name>
<surname>Potus</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dasgupta</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K. H.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Macrophage-NLRP3 activation promotes right ventricle failure in pulmonary arterial hypertension</article-title>. <source>Am. J. Resp. Crit. Care</source> <volume>206</volume>, <fpage>608</fpage>&#x2013;<lpage>624</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.202110-2274OC</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alastalo</surname>
<given-names>T. P.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>V. D.</given-names>
</name>
<name>
<surname>Pham</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J. K.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Disruption of PPAR&#x3b3;/&#x3b2;-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival</article-title>. <source>J. Clin. Invest</source> <volume>121</volume>, <fpage>3735</fpage>&#x2013;<lpage>3746</lpage>. <pub-id pub-id-type="doi">10.1172/JCI43382</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atkinson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Upton</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>Machado</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Trembath</surname>
<given-names>R. C.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor</article-title>. <source>Circulation</source> <volume>105</volume>, <fpage>1672</fpage>&#x2013;<lpage>1678</lpage>. <pub-id pub-id-type="doi">10.1161/01.cir.0000012754.72951.3d</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bai</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Z. B.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>G. S.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G. S.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>SOCS3 was induced by hypoxia and suppressed STAT3 phosphorylation in pulmonary arterial smooth muscle cells</article-title>. <source>Resp. Physiol. Neurobi</source> <volume>152</volume>, <fpage>83</fpage>&#x2013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.resp.2005.07.001</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banks</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Gerasimovskaya</surname>
<given-names>E. V.</given-names>
</name>
<name>
<surname>Tucker</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Frid</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Carpenter</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Stenmark</surname>
<given-names>K. R.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Egr-1 antisense oligonucleotides inhibit hypoxia-induced proliferation of pulmonary artery adventitial fibroblasts</article-title>. <source>J. Appl. Physiol.</source> <volume>98</volume>, <fpage>732</fpage>&#x2013;<lpage>738</lpage>. <pub-id pub-id-type="doi">10.1152/japplphysiol.00821.2004</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berk</surname>
<given-names>B. C.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Vascular smooth muscle growth: Autocrine growth mechanisms</article-title>. <source>Physiol. Rev.</source> <volume>81</volume>, <fpage>999</fpage>&#x2013;<lpage>1030</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.2001.81.3.999</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernkopf</surname>
<given-names>D. B.</given-names>
</name>
<name>
<surname>Bruckner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hadjihannas</surname>
<given-names>M. V.</given-names>
</name>
<name>
<surname>Behrens</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>An aggregon in conductin/axin2 regulates Wnt/&#x3b2;-catenin signaling and holds potential for cancer therapy</article-title>. <source>Nat. Commun.</source> <volume>10</volume>, <fpage>4251</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-12203-8</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertero</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cottrill</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Haeger</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Dieffenbach</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Annis</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Matrix remodeling promotes pulmonary hypertension through feedback mechanoactivation of the YAP/TAZ-miR-130/301 circuit</article-title>. <source>Cell Rep.</source> <volume>13</volume>, <fpage>1016</fpage>&#x2013;<lpage>1032</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2015.09.049</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertero</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Oldham</surname>
<given-names>W. M.</given-names>
</name>
<name>
<surname>Cottrill</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Pisano</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vanderpool</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension</article-title>. <source>J. Clin. Invest</source> <volume>126</volume>, <fpage>3313</fpage>&#x2013;<lpage>3335</lpage>. <pub-id pub-id-type="doi">10.1172/JCI86387</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biasin</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Egemnazarov</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wilhelm</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ghanim</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Klepetko</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Meprin beta, a novel mediator of vascular remodelling underlying pulmonary hypertension</article-title>. <source>J. Pathol.</source> <volume>233</volume>, <fpage>7</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1002/path.4303</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bierer</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nitta</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Codianni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>de Frutos</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dominguez-Bautista</surname>
<given-names>J. A.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>NFATc3 is required for chronic hypoxia-induced pulmonary hypertension in adult and neonatal mice</article-title>. <source>Am. J. Physiol. Lung Cell Mol. Physiol.</source> <volume>301</volume>, <fpage>L872</fpage>&#x2013;<lpage>L880</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00405.2010</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonnet</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rochefort</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sutendra</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Archer</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Haromy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted</article-title>. <source>Proc. Natl. Acad. Sci. U S A</source> <volume>104</volume>, <fpage>11418</fpage>&#x2013;<lpage>11423</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0610467104</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bourgeois</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Habbout</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ranchoux</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Paquet-Marceau</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Trinh</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension</article-title>. <source>J. Mol. Med. Berl.</source> <volume>96</volume>, <fpage>223</fpage>&#x2013;<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1007/s00109-017-1619-0</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brock</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trenkmann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gay</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Michel</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Gay</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fischler</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway</article-title>. <source>Circ. Res.</source> <volume>104</volume>, <fpage>1184</fpage>&#x2013;<lpage>1191</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.197491</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S. Y.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Nanoparticle endothelial delivery of PGC-1 alpha attenuates hypoxia-induced pulmonary hypertension by attenuating EndoMT-caused vascular wall remodeling</article-title>. <source>Redox Biol.</source> <volume>58</volume>, <fpage>102524</fpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2022.102524</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calvier</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chouvarine</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Legchenko</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Geldner</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Borchert</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>PPAR&#x3b3; links BMP2 and TGF&#x3b2;1 pathways in vascular smooth muscle cells, regulating cell proliferation and glucose metabolism</article-title>. <source>Cell Metab.</source> <volume>25</volume>, <fpage>1118</fpage>&#x2013;<lpage>1134</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2017.03.011</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The IRE1&#x3b1;-XBP1 pathway function in hypoxia-induced pulmonary vascular remodeling, is upregulated by quercetin, inhibits apoptosis and partially reverses the effect of quercetin in PASMCs</article-title>. <source>Am. J. Transl. Res.</source> <volume>11</volume>, <fpage>641</fpage>&#x2013;<lpage>654</lpage>.</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>G. L.</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice</article-title>. <source>J. Exp. Med.</source> <volume>215</volume>, <fpage>2175</fpage>&#x2013;<lpage>2195</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20171767</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Berberine attenuates hypoxia-induced pulmonary arterial hypertension via bone morphogenetic protein and transforming growth factor-beta signaling</article-title>. <source>J. Cell Physiol.</source> <volume>234</volume>, <fpage>17482</fpage>&#x2013;<lpage>17493</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.28370</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chinnadurai</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>The transcriptional corepressor CtBP: A foe of multiple tumor suppressors</article-title>. <source>Cancer Res.</source> <volume>69</volume>, <fpage>731</fpage>&#x2013;<lpage>734</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-3349</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname>
<given-names>Y. B.</given-names>
</name>
<name>
<surname>Xiangli</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Regulatory T cells protect against hypoxia-induced pulmonary arterial hypertension in mice</article-title>. <source>Mol. Med. Rep.</source> <volume>11</volume>, <fpage>3181</fpage>&#x2013;<lpage>3187</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2014.3106</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Courboulin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tremblay</surname>
<given-names>V. L.</given-names>
</name>
<name>
<surname>Barrier</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Meloche</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Chapolard</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Kruppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension</article-title>. <source>Respir. Res.</source> <volume>12</volume>, <fpage>128</fpage>. <pub-id pub-id-type="doi">10.1186/1465-9921-12-128</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cowan</surname>
<given-names>K. N.</given-names>
</name>
<name>
<surname>Heilbut</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Humpl</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rabinovitch</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor</article-title>. <source>Nat. Med.</source> <volume>6</volume>, <fpage>698</fpage>&#x2013;<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1038/76282</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cowburn</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Crosby</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Macias</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Branco</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Colaco</surname>
<given-names>R. D. D. R.</given-names>
</name>
<name>
<surname>Southwood</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>HIF2 alpha-arginase axis is essential for the development of pulmonary hypertension</article-title>. <source>P Natl. Acad. Sci. USA</source> <volume>113</volume>, <fpage>8801</fpage>&#x2013;<lpage>8806</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1602978113</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cufi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vazquez-Martin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Oliveras-Ferraros</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Martin-Castillo</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Joven</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Menendez</surname>
<given-names>J. A.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Metformin against TGF beta-induced epithelial-to-mesenchymal transition (EMT) from cancer stem cells to aging-associated fibrosis</article-title>. <source>Cell Cycle</source> <volume>9</volume>, <fpage>4461</fpage>&#x2013;<lpage>4468</lpage>. <pub-id pub-id-type="doi">10.4161/cc.9.22.14048</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dabral</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Muecke</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Valasarajan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schmoranzer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wietelmann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Semenza</surname>
<given-names>G. L.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>A RASSF1A-HIF1&#x3b1; loop drives Warburg effect in cancer and pulmonary hypertension</article-title>. <source>Nat. Commun.</source> <volume>10</volume>, <fpage>2130</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-10044-z</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dabral</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Kojonazarov</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Savai</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ghofrani</surname>
<given-names>H. A.</given-names>
</name>
<name>
<surname>Weissmann</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension</article-title>. <source>Eur. Respir. J.</source> <volume>48</volume>, <fpage>1137</fpage>&#x2013;<lpage>1149</lpage>. <pub-id pub-id-type="doi">10.1183/13993003.00773-2015</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Raychaudhuri</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2018a</year>). <article-title>Smooth muscle cell-specific FoxM1 controls hypoxia-induced pulmonary hypertension</article-title>. <source>Cell Signal</source> <volume>51</volume>, <fpage>119</fpage>&#x2013;<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2018.08.003</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname>
<given-names>Z. Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wharton</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y. Y.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Prolyl-4 hydroxylase 2 (PHD2) deficiency in endothelial cells and hematopoietic cells induces obliterative vascular remodeling and severe pulmonary arterial hypertension in mice and humans through hypoxia-inducible factor-2&#x3b1;</article-title>. <source>Circulation</source> <volume>133</volume>, <fpage>2447</fpage>&#x2013;<lpage>2458</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.021494</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname>
<given-names>Z. Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Machireddy</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>Z. J.</given-names>
</name>
<etal/>
</person-group> (<year>2018b</year>). <article-title>Endothelial and smooth muscle cell interaction via FoxM1 signaling mediates vascular remodeling and pulmonary hypertension</article-title>. <source>Am. J. Resp. Crit. Care</source> <volume>198</volume>, <fpage>788</fpage>&#x2013;<lpage>802</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201709-1835OC</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Zawada</surname>
<given-names>W. M.</given-names>
</name>
<name>
<surname>Stenmark</surname>
<given-names>K. R.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Hypoxia exposure induces the emergence of fibroblasts lacking replication repressor signals of PKCzeta in the pulmonary artery adventitia</article-title>. <source>Cardiovasc Res.</source> <volume>78</volume>, <fpage>440</fpage>&#x2013;<lpage>448</lpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvn014</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Frutos</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Spangler</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Alo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bosc</surname>
<given-names>L. V.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>NFATc3 mediates chronic hypoxia-induced pulmonary arterial remodeling with alpha-actin up-regulation</article-title>. <source>J. Biol. Chem.</source> <volume>282</volume>, <fpage>15081</fpage>&#x2013;<lpage>15089</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M702679200</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Gassart</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Martinon</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Pyroptosis: Caspase-11 unlocks the gates of death</article-title>. <source>Immunity</source> <volume>43</volume>, <fpage>835</fpage>&#x2013;<lpage>837</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2015.10.024</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeLeon-Pennell</surname>
<given-names>K. Y.</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Lindsey</surname>
<given-names>M. L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Fibroblasts: The arbiters of extracellular matrix remodeling</article-title>. <source>Matrix Biol.</source> <volume>91-92</volume>, <fpage>1</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.matbio.2020.05.006</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diebold</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hennigs</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Miyagawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C. Y. G.</given-names>
</name>
<name>
<surname>Nickel</surname>
<given-names>N. P.</given-names>
</name>
<name>
<surname>Kaschwich</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension</article-title>. <source>Cell Metab.</source> <volume>21</volume>, <fpage>596</fpage>&#x2013;<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2015.03.010</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dromparis</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Paulin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Stenson</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Haromy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sutendra</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Michelakis</surname>
<given-names>E. D.</given-names>
</name>
</person-group> (<year>2013a</year>). <article-title>Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension</article-title>. <source>Circulation</source> <volume>127</volume>, <fpage>115</fpage>&#x2013;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.133413</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dromparis</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Paulin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sutendra</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Bonnet</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Michelakis</surname>
<given-names>E. D.</given-names>
</name>
</person-group> (<year>2013b</year>). <article-title>Uncoupling protein 2 deficiency mimics the effects of hypoxia and endoplasmic reticulum stress on mitochondria and triggers pseudohypoxic pulmonary vascular remodeling and pulmonary hypertension</article-title>. <source>Circ. Res.</source> <volume>113</volume>, <fpage>126</fpage>&#x2013;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.112.300699</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dupont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Morsut</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Aragona</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Enzo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Giulitti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cordenonsi</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Role of YAP/TAZ in mechanotransduction</article-title>. <source>Nature</source> <volume>474</volume>, <fpage>179</fpage>&#x2013;<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1038/nature10137</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eichstaedt</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Viales</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Benjamin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>First identification of Kruppel-like factor 2 mutation in heritable pulmonary arterial hypertension</article-title>. <source>Clin. Sci. (Lond).</source> <volume>131</volume>, <fpage>689</fpage>&#x2013;<lpage>698</lpage>. <pub-id pub-id-type="doi">10.1042/CS20160930</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eijkelenboom</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Burgering</surname>
<given-names>B. M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>FOXOs: Signalling integrators for homeostasis maintenance</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>14</volume>, <fpage>83</fpage>&#x2013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3507</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El Kasmi</surname>
<given-names>K. C.</given-names>
</name>
<name>
<surname>Pugliese</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Riddle</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Poth</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Frid</surname>
<given-names>M. G.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension</article-title>. <source>J. Immunol.</source> <volume>193</volume>, <fpage>597</fpage>&#x2013;<lpage>609</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1303048</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname>
<given-names>C. E.</given-names>
</name>
<name>
<surname>Cober</surname>
<given-names>N. D.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y. Y.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Endothelial cells in the pathogenesis of pulmonary arterial hypertension</article-title>. <source>Eur. Respir. J.</source> <volume>58</volume>, <fpage>2003957</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.03957-2020</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sinn</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Klepetko</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>TWIST1 drives smooth muscle cell proliferation in pulmonary hypertension via loss of GATA-6 and BMPR2</article-title>. <source>Am. J. Resp. Crit. Care</source> <volume>202</volume>, <fpage>1283</fpage>&#x2013;<lpage>1296</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201909-1884OC</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farkas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Alhussaini</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Kraskauskas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kraskauskiene</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Cool</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>Nicolls</surname>
<given-names>M. R.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Nuclear factor kappa B inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats</article-title>. <source>Am. J. Resp. Cell Mol.</source> <volume>51</volume>, <fpage>413</fpage>&#x2013;<lpage>425</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2013-0355OC</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fric</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zelante</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>A. Y.</given-names>
</name>
<name>
<surname>Mertes</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H. B.</given-names>
</name>
<name>
<surname>Ricciardi-Castagnoli</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>NFAT control of innate immunity</article-title>. <source>Blood</source> <volume>120</volume>, <fpage>1380</fpage>&#x2013;<lpage>1389</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2012-02-404475</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frid</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Kale</surname>
<given-names>V. A.</given-names>
</name>
<name>
<surname>Stenmark</surname>
<given-names>K. R.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation - <italic>in vitro</italic> analysis</article-title>. <source>Circ. Res.</source> <volume>90</volume>, <fpage>1189</fpage>&#x2013;<lpage>1196</lpage>. <pub-id pub-id-type="doi">10.1161/01.res.0000021432.70309.28</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galis</surname>
<given-names>Z. S.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Godin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Magid</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shipley</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Senior</surname>
<given-names>R. M.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling</article-title>. <source>Circ. Res.</source> <volume>91</volume>, <fpage>852</fpage>&#x2013;<lpage>859</lpage>. <pub-id pub-id-type="doi">10.1161/01.res.0000041036.86977.14</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fa</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Up-regulation of caveolin-1 by DJ-1 attenuates rat pulmonary arterial hypertension by inhibiting TGF&#x3b2;/Smad signaling pathway</article-title>. <source>Exp. Cell Res.</source> <volume>361</volume>, <fpage>192</fpage>&#x2013;<lpage>198</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2017.10.019</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerasimovskaya</surname>
<given-names>E. V.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>P. L.</given-names>
</name>
<name>
<surname>Carpenter</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Stenmark</surname>
<given-names>K. R.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Extracellular ATP is an autocrine/paracrine regulator of hypoxia-induced adventitial fibroblast growth - signaling through extracellular signal-regulated kinase-1/2 and the Egr-1 transcription factor</article-title>. <source>J. Biol. Chem.</source> <volume>277</volume>, <fpage>44638</fpage>&#x2013;<lpage>44650</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M203012200</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghatnekar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chrobak</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Reese</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Stawski</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Seta</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wirrig</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Endothelial GATA-6 deficiency promotes pulmonary arterial hypertension</article-title>. <source>Am. J. Pathol.</source> <volume>182</volume>, <fpage>2391</fpage>&#x2013;<lpage>2406</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2013.02.039</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomez-Puerto</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>van Zuijen</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Szulcek</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>van Dinther</surname>
<given-names>M. A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension</article-title>. <source>J. Pathol.</source> <volume>249</volume>, <fpage>356</fpage>&#x2013;<lpage>367</lpage>. <pub-id pub-id-type="doi">10.1002/path.5322</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez Bosc</surname>
<given-names>L. V.</given-names>
</name>
<name>
<surname>Layne</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Hill-Eubanks</surname>
<given-names>D. C.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Nuclear factor of activated T cells and serum response factor cooperatively regulate the activity of an alpha-actin intronic enhancer</article-title>. <source>J. Biol. Chem.</source> <volume>280</volume>, <fpage>26113</fpage>&#x2013;<lpage>26120</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M411972200</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graf</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Haimel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bleda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hadinnapola</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Southgate</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Identification of rare sequence variation underlying heritable pulmonary arterial hypertension</article-title>. <source>Nat. Commun.</source> <volume>9</volume>, <fpage>1416</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-03672-4</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H. M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Forkhead box M1 transcription factor: A novel target for pulmonary arterial hypertension therapy</article-title>. <source>World J. Pediatr.</source> <volume>16</volume>, <fpage>113</fpage>&#x2013;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1007/s12519-019-00271-1</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto-Kataoka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hosen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sonobe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Arita</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yasui</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Masaki</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension</article-title>. <source>P Natl. Acad. Sci. USA</source> <volume>112</volume>, <fpage>E2677</fpage>&#x2013;<lpage>E2686</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1424774112</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hassoun</surname>
<given-names>P. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Pulmonary arterial hypertension</article-title>. <source>New Engl. J. Med.</source> <volume>385</volume>, <fpage>2361</fpage>&#x2013;<lpage>2376</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra2000348</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hata</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y. G.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>TGF-Beta signaling from receptors to smads</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source> <volume>8</volume>, <fpage>a022061</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a022061</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>GLI1-mediated pulmonary artery smooth muscle cell pyroptosis contributes to hypoxia-induced pulmonary hypertension</article-title>. <source>Am. J. Physiol. Lung Cell Mol. Physiol.</source> <volume>318</volume>, <fpage>L472</fpage>&#x2013;<lpage>L482</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00405.2019</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hennigs</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>A. Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C. Y. G.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Mienert</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Miyagawa</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>PPAR gamma-p53-Mediated vasculoregenerative program to reverse pulmonary hypertension</article-title>. <source>Circ. Res.</source> <volume>128</volume>, <fpage>401</fpage>&#x2013;<lpage>418</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.316339</pub-id>
</citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heukels</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Corneth</surname>
<given-names>O. B. J.</given-names>
</name>
<name>
<surname>van Uden</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>van Hulst</surname>
<given-names>J. A. C.</given-names>
</name>
<name>
<surname>van den Toorn</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>van den Bosch</surname>
<given-names>A. E.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Loss of immune homeostasis in patients with idiopathic pulmonary arterial hypertension</article-title>. <source>Thorax</source> <volume>76</volume>, <fpage>1209</fpage>&#x2013;<lpage>1218</lpage>. <pub-id pub-id-type="doi">10.1136/thoraxjnl-2020-215460</pub-id>
</citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hiraide</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kataoka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Aimi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chiba</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kanekura</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>SOX17 mutations in Japanese patients with pulmonary arterial hypertension</article-title>. <source>Am. J. Resp. Crit. Care</source> <volume>198</volume>, <fpage>1231</fpage>&#x2013;<lpage>1233</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201804-0766LE</pub-id>
</citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hopper</surname>
<given-names>R. K.</given-names>
</name>
<name>
<surname>Moonen</surname>
<given-names>J. R. A. J.</given-names>
</name>
<name>
<surname>Diebold</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>A. Q.</given-names>
</name>
<name>
<surname>Rhodes</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Tojais</surname>
<given-names>N. F.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>In pulmonary arterial hypertension, reduced BMPR2 promotes endothelial-to-mesenchymal transition via HMGA1 and its target slug</article-title>. <source>Circulation</source> <volume>133</volume>, <fpage>1783</fpage>&#x2013;<lpage>1794</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.020617</pub-id>
</citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Poth</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Flockton</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Laux</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension</article-title>. <source>Eur. Respir. J.</source> <volume>54</volume>, <fpage>1900378</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.00378-2019</pub-id>
</citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J. S.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>TGF-beta control of cell proliferation</article-title>. <source>J. Cell Biochem</source> <volume>96</volume>, <fpage>447</fpage>&#x2013;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.20558</pub-id>
</citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Humbert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guignabert</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bonnet</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dorfmuller</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Klinger</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Nicolls</surname>
<given-names>M. R.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives</article-title>. <source>Eur. Respir. J.</source> <volume>53</volume>, <fpage>1801887</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.01887-2018</pub-id>
</citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Humbert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kovacs</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hoeper</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Badagliacca</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>R. M. F.</given-names>
</name>
<name>
<surname>Brida</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension</article-title>. <source>Eur. Respir. J.</source> <volume>61</volume>, <fpage>2200879</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.00879-2022</pub-id>
</citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Humbert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>McLaughlin</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gibbs</surname>
<given-names>J. S. R.</given-names>
</name>
<name>
<surname>Gomberg-Maitland</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hoeper</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Preston</surname>
<given-names>I. R.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Sotatercept for the treatment of pulmonary arterial hypertension</article-title>. <source>N. Engl. J. Med.</source> <volume>384</volume>, <fpage>1204</fpage>&#x2013;<lpage>1215</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2024277</pub-id>
</citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Humbert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>McLaughlin</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gibbs</surname>
<given-names>J. S. R.</given-names>
</name>
<name>
<surname>Gomberg-Maitland</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hoeper</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Preston</surname>
<given-names>I. R.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension</article-title>. <source>Eur. Respir. J.</source> <volume>61</volume>, <fpage>2201347</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.01347-2022</pub-id>
</citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeong</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Pereira</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>So</surname>
<given-names>E. Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>K. Q.</given-names>
</name>
<name>
<surname>Del Tatto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Targeting RUNX1 as a novel treatment modality for pulmonary arterial hypertension</article-title>. <source>Cardiovasc Res.</source> <volume>118</volume>, <fpage>3211</fpage>&#x2013;<lpage>3224</lpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvac001</pub-id>
</citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>F. S.</given-names>
</name>
<name>
<surname>Meech</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Edelman</surname>
<given-names>D. B.</given-names>
</name>
<name>
<surname>Oakey</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>P. L.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Prx1 controls vascular smooth muscle cell proliferation and tenascin-C expression and is upregulated with Prx2 in pulmonary vascular disease</article-title>. <source>Circ. Res.</source> <volume>89</volume>, <fpage>131</fpage>&#x2013;<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1161/hh1401.093582</pub-id>
</citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>B. Y.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>K. K.</given-names>
</name>
<name>
<surname>Kleinhenz</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Bijli</surname>
<given-names>K. M.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Peroxisome proliferator-activated receptor gamma and microRNA 98 in hypoxia-induced endothelin-1 signaling</article-title>. <source>Am. J. Resp. Cell Mol.</source> <volume>54</volume>, <fpage>136</fpage>&#x2013;<lpage>146</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2014-0337OC</pub-id>
</citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kerstjens-Frederikse</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>Bongers</surname>
<given-names>E. M. H. F.</given-names>
</name>
<name>
<surname>Roofthooft</surname>
<given-names>M. T. R.</given-names>
</name>
<name>
<surname>Leter</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Douwes</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Van Dijk</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension</article-title>. <source>J. Med. Genet.</source> <volume>50</volume>, <fpage>500</fpage>&#x2013;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1136/jmedgenet-2012-101152</pub-id>
</citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klemm</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Majka</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Crossno</surname>
<given-names>J. T.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Psilas</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Reusch</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Garat</surname>
<given-names>C. V.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Reduction of reactive oxygen species prevents hypoxia-induced CREB depletion in pulmonary artery smooth muscle cells</article-title>. <source>J. Cardiovasc Pharmacol.</source> <volume>58</volume>, <fpage>181</fpage>&#x2013;<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1097/FJC.0b013e31821f2773</pub-id>
</citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kokudo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yoshimatsu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamazaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Watabe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Miyazono</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Snail is required for TGFbeta-induced endothelial-mesenchymal transition of embryonic stem cell-derived endothelial cells</article-title>. <source>J. Cell Sci.</source> <volume>121</volume>, <fpage>3317</fpage>&#x2013;<lpage>3324</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.028282</pub-id>
</citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kovacs</surname>
<given-names>S. B.</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>E. A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Gasdermins: Effectors of pyroptosis</article-title>. <source>Trends Cell Biol.</source> <volume>27</volume>, <fpage>673</fpage>&#x2013;<lpage>684</lpage>. <pub-id pub-id-type="doi">10.1016/j.tcb.2017.05.005</pub-id>
</citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kudryashova</surname>
<given-names>T. V.</given-names>
</name>
<name>
<surname>Dabral</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nayakanti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Goncharov</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Avolio</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Noncanonical HIPPO/MST signaling via BUB3 and FOXO drives pulmonary vascular cell growth and survival</article-title>. <source>Circ. Res.</source> <volume>130</volume>, <fpage>760</fpage>&#x2013;<lpage>778</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.319100</pub-id>
</citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kudryashova</surname>
<given-names>T. V.</given-names>
</name>
<name>
<surname>Goncharov</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Pena</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Vanderpool</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Baust</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>HIPPO-Integrin-linked kinase cross-talk controls self-sustaining proliferation and survival in pulmonary hypertension</article-title>. <source>Am. J. Respir. Crit. Care Med.</source> <volume>194</volume>, <fpage>866</fpage>&#x2013;<lpage>877</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201510-2003OC</pub-id>
</citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lane</surname>
<given-names>K. B.</given-names>
</name>
<name>
<surname>Machado</surname>
<given-names>R. D.</given-names>
</name>
<name>
<surname>Pauciulo</surname>
<given-names>M. W.</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Loyd</surname>
<given-names>J. E.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension</article-title>. <source>Nat. Genet.</source> <volume>26</volume>, <fpage>81</fpage>&#x2013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1038/79226</pub-id>
</citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>H. W.</given-names>
</name>
<name>
<surname>Adachi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pak</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>BMPR1A promotes ID2-ZEB1 interaction to suppress excessive endothelial to mesenchymal transition</article-title>. <source>Cardiovasc Res.</source> <volume>27</volume>, <fpage>cvac159</fpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvac159</pub-id>
</citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>K. W.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>N. K.</given-names>
</name>
<name>
<surname>Ham</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Roh</surname>
<given-names>T. Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S. H.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Twist1 is essential in maintaining mesenchymal state and tumor-initiating properties in synovial sarcoma</article-title>. <source>Cancer Lett.</source> <volume>343</volume>, <fpage>62</fpage>&#x2013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2013.09.013</pub-id>
</citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Alastalo</surname>
<given-names>T. P.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Autophagic protein LC3B confers resistance against hypoxia-induced pulmonary hypertension</article-title>. <source>Am. J. Respir. Crit. Care Med.</source> <volume>183</volume>, <fpage>649</fpage>&#x2013;<lpage>658</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201005-0746OC</pub-id>
</citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Legchenko</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Chouvarine</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Borchert</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fernandez-Gonzalez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Snay</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Meier</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>PPAR gamma agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation</article-title>. <source>Sci. Transl. Med.</source> <volume>10</volume>, <fpage>eaao0303</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aao0303</pub-id>
</citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lehrke</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lazar</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>The many faces of PPAR gamma</article-title>. <source>Cell</source> <volume>123</volume>, <fpage>993</fpage>&#x2013;<lpage>999</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2005.11.026</pub-id>
</citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Nie</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>M. B.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Small-molecule inhibitor LF3 restrains the development of pulmonary hypertension through the Wnt/&#x3b2;-catenin pathway</article-title>. <source>Acta Bioch Bioph Sin.</source> <volume>53</volume>, <fpage>1277</fpage>&#x2013;<lpage>1289</lpage>. <pub-id pub-id-type="doi">10.1093/abbs/gmab103</pub-id>
</citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Riddle</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Frid</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>El Kasmi</surname>
<given-names>K. C.</given-names>
</name>
<name>
<surname>McKinsey</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Sokol</surname>
<given-names>R. J.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension</article-title>. <source>J. Immunol.</source> <volume>187</volume>, <fpage>2711</fpage>&#x2013;<lpage>2722</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1100479</pub-id>
</citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Riddle</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>D&#x27;Alessandro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Flockton</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Serkova</surname>
<given-names>N. J.</given-names>
</name>
<etal/>
</person-group> (<year>2016a</year>). <article-title>Metabolic reprogramming regulates the proliferative and inflammatory phenotype of adventitial fibroblasts in pulmonary hypertension through the transcriptional corepressor C-terminal binding protein-1</article-title>. <source>Circulation</source> <volume>134</volume>, <fpage>1105</fpage>&#x2013;<lpage>1121</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.023171</pub-id>
</citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vattulainen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Aho</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Orcholski</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rojas</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension</article-title>. <source>Am. J. Respir. Cell Mol. Biol.</source> <volume>50</volume>, <fpage>1118</fpage>&#x2013;<lpage>1128</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2013-0349OC</pub-id>
</citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2016b</year>). <article-title>KLF5 mediates vascular remodeling via HIF-1&#x3b1; in hypoxic pulmonary hypertension</article-title>. <source>Am. J. Physiol. Lung Cell Mol. Physiol.</source> <volume>310</volume>, <fpage>L299</fpage>&#x2013;<lpage>L310</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00189.2015</pub-id>
</citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Leathers</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Makino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Parsa</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Notch3 signaling promotes the development of pulmonary arterial hypertension</article-title>. <source>Nat. Med.</source> <volume>15</volume>, <fpage>1289</fpage>&#x2013;<lpage>1297</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2021</pub-id>
</citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y. Z.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>X. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Kinesin family member 23, regulated by FOXM1, promotes triple negative breast cancer progression via activating Wnt/&#x3b2;-catenin pathway</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>41</volume>, <fpage>168</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-022-02373-7</pub-id>
</citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Resolvin E1 attenuates pulmonary hypertension by suppressing wnt7a/&#x3b2;-catenin signaling</article-title>. <source>Hypertension</source> <volume>78</volume>, <fpage>1914</fpage>&#x2013;<lpage>1926</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.121.17809</pub-id>
</citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>H. T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Knockdown of HSP110 attenuates hypoxia-induced pulmonary hypertension in mice through suppression of YAP/TAZ-TEAD4 pathway</article-title>. <source>Resp. Res.</source> <volume>23</volume>, <fpage>209</fpage>. <pub-id pub-id-type="doi">10.1186/s12931-022-02124-4</pub-id>
</citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>K. W.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>IL-33 initiates vascular remodelling in hypoxic pulmonary hypertension by up-regulating HIF-1 alpha and VEGF expression in vascular endothelial cells</article-title>. <source>Ebiomedicine</source> <volume>33</volume>, <fpage>196</fpage>&#x2013;<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2018.06.003</pub-id>
</citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>R. F.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X. W.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Snail1 mediates hypoxia-induced melanoma progression</article-title>. <source>Am. J. Pathol.</source> <volume>179</volume>, <fpage>3020</fpage>&#x2013;<lpage>3031</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2011.08.038</pub-id>
</citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Long</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Southwood</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Marciniak</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Dunmore</surname>
<given-names>B. J.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation</article-title>. <source>Circ. Res.</source> <volume>112</volume>, <fpage>1159</fpage>&#x2013;<lpage>1170</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.300483</pub-id>
</citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Looney</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Stawski</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Marden</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Iwamoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trojanowska</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Synergistic role of endothelial ERG and FLI1 in mediating pulmonary vascular homeostasis</article-title>. <source>Am. J. Respir. Cell Mol. Biol.</source> <volume>57</volume>, <fpage>121</fpage>&#x2013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2016-0200OC</pub-id>
</citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luks</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Hackett</surname>
<given-names>P. H.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Medical conditions and high-altitude travel</article-title>. <source>N. Engl. J. Med.</source> <volume>386</volume>, <fpage>364</fpage>&#x2013;<lpage>373</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra2104829</pub-id>
</citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>D. Y.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W. Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C. D.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Runt-related transcription factor 1 (RUNX1) binds to p50 in macrophages and enhances TLR4-triggered inflammation and septic shock</article-title>. <source>J. Biol. Chem.</source> <volume>291</volume>, <fpage>22011</fpage>&#x2013;<lpage>22020</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M116.715953</pub-id>
</citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>CD146-HIF-1&#x3b1; hypoxic reprogramming drives vascular remodeling and pulmonary arterial hypertension</article-title>. <source>Nat. Commun.</source> <volume>10</volume>, <fpage>3551</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-11500-6</pub-id>
</citation>
</ref>
<ref id="B102">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mammoto</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mammoto</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Role of Twist1 phosphorylation in angiogenesis and pulmonary fibrosis</article-title>. <source>Am. J. Resp. Cell Mol.</source> <volume>55</volume>, <fpage>633</fpage>&#x2013;<lpage>644</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2016-0012OC</pub-id>
</citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mammoto</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Muyleart</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Konduri</surname>
<given-names>G. G.</given-names>
</name>
<name>
<surname>Mammoto</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Twist1 in hypoxia-induced pulmonary hypertension through transforming growth factor-beta-smad signaling</article-title>. <source>Am. J. Resp. Cell Mol.</source> <volume>58</volume>, <fpage>194</fpage>&#x2013;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2016-0323OC</pub-id>
</citation>
</ref>
<ref id="B104">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Okazawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Asano</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Inagaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ishibashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yamagishi</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension</article-title>. <source>P Natl. Acad. Sci. USA</source> <volume>118</volume>, <fpage>e2023899118</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2023899118</pub-id>
</citation>
</ref>
<ref id="B105">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maurer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Reich</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Juengel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kriegsmann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gay</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Schett</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis</article-title>. <source>Ann. Rheum. Dis.</source> <volume>71</volume>, <fpage>1382</fpage>&#x2013;<lpage>1387</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2011-200940</pub-id>
</citation>
</ref>
<ref id="B106">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McConnell</surname>
<given-names>B. B.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>V. W.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Mammalian Kruppel-like factors in health and diseases</article-title>. <source>Physiol. Rev.</source> <volume>90</volume>, <fpage>1337</fpage>&#x2013;<lpage>1381</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00058.2009</pub-id>
</citation>
</ref>
<ref id="B107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McMurtry</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Bonnet</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X. C.</given-names>
</name>
<name>
<surname>Dyck</surname>
<given-names>J. R. B.</given-names>
</name>
<name>
<surname>Haromy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis</article-title>. <source>Circ. Res.</source> <volume>95</volume>, <fpage>830</fpage>&#x2013;<lpage>840</lpage>. <pub-id pub-id-type="doi">10.1161/01.RES.0000145360.16770.9f</pub-id>
</citation>
</ref>
<ref id="B108">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sakuma</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ohira</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kasukawa</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Athymic nude rats develop severe pulmonary hypertension following monocrotaline administration</article-title>. <source>Int. Arch. Allergy Imm</source> <volume>121</volume>, <fpage>246</fpage>&#x2013;<lpage>252</lpage>. <pub-id pub-id-type="doi">10.1159/000024324</pub-id>
</citation>
</ref>
<ref id="B109">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizuno</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bogaard</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Kraskauskas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Alhussaini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gomez-Arroyo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Voelkel</surname>
<given-names>N. F.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice</article-title>. <source>Am. J. Physiol-Lung C</source> <volume>300</volume>, <fpage>L753</fpage>&#x2013;<lpage>L761</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00286.2010</pub-id>
</citation>
</ref>
<ref id="B110">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizuno</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Farkas</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Al Husseini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Farkas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gomez-Arroyo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kraskauskas</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization</article-title>. <source>Am. J. Resp. Cell Mol.</source> <volume>47</volume>, <fpage>679</fpage>&#x2013;<lpage>687</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2012-0077OC</pub-id>
</citation>
</ref>
<ref id="B111">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mouraret</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Marcos</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Abid</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gary-Bobo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Saker</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Houssaini</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension</article-title>. <source>Circulation</source> <volume>127</volume>, <fpage>1664</fpage>&#x2013;<lpage>1676</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.002434</pub-id>
</citation>
</ref>
<ref id="B112">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Myatt</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>E. W. F.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Targeting FOXM1</article-title>. <source>Nat. Rev. Cancer</source> <volume>8</volume>, <fpage>242</fpage>&#x2013;<lpage>244</lpage>. <pub-id pub-id-type="doi">10.1038/nrc2223-c2</pub-id>
</citation>
</ref>
<ref id="B113">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakahama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hanieh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>N. T.</given-names>
</name>
<name>
<surname>Chinen</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ripley</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Millrine</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Aryl hydrocarbon receptor-mediated induction of the microRNA-132/212 cluster promotes interleukin-17-producing T-helper cell differentiation</article-title>. <source>P Natl. Acad. Sci. USA</source> <volume>110</volume>, <fpage>11964</fpage>&#x2013;<lpage>11969</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1311087110</pub-id>
</citation>
</ref>
<ref id="B114">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nave</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Mizikova</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Niess</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Steenbock</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Reichenberger</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Talavera</surname>
<given-names>M. L.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source> <volume>34</volume>, <fpage>1446</fpage>&#x2013;<lpage>1458</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.114.303534</pub-id>
</citation>
</ref>
<ref id="B115">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nie</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Periostin: A potential therapeutic target for pulmonary hypertension?</article-title> <source>Circ. Res.</source> <volume>127</volume>, <fpage>1138</fpage>&#x2013;<lpage>1152</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.316943</pub-id>
</citation>
</ref>
<ref id="B116">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nimmakayalu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Major</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sheffield</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Solomon</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Patil</surname>
<given-names>S. R.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Microdeletion of 17q22q23.2 encompassing TBX2 and TBX4 in a patient with congenital microcephaly, thyroid duct cyst, sensorineural hearing loss, and pulmonary hypertension</article-title>. <source>Am. J. Med. Genet. A</source> <volume>155a</volume>, <fpage>418</fpage>&#x2013;<lpage>423</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.33827</pub-id>
</citation>
</ref>
<ref id="B117">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nusse</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Clevers</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Wnt/&#x3b2;-Catenin signaling, disease, and emerging therapeutic modalities</article-title>. <source>Cell</source> <volume>169</volume>, <fpage>985</fpage>&#x2013;<lpage>999</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.05.016</pub-id>
</citation>
</ref>
<ref id="B118">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O&#x27;Shea</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Villarino</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Gadina</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>McInnes</surname>
<given-names>I. B.</given-names>
</name>
<name>
<surname>Laurence</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>The JAK-STAT pathway: Impact on human disease and therapeutic intervention</article-title>. <source>Annu Rev. Med.</source> <volume>66</volume>, <fpage>311</fpage>&#x2013;<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-med-051113-024537</pub-id>
</citation>
</ref>
<ref id="B119">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oellerich</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Potente</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>FOXOs and sirtuins in vascular growth, maintenance, and aging</article-title>. <source>Circ. Res.</source> <volume>110</volume>, <fpage>1238</fpage>&#x2013;<lpage>1251</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.246488</pub-id>
</citation>
</ref>
<ref id="B120">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owens</surname>
<given-names>G. K.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Wamhoff</surname>
<given-names>B. R.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Molecular regulation of vascular smooth muscle cell differentiation in development and disease</article-title>. <source>Physiol. Rev.</source> <volume>84</volume>, <fpage>767</fpage>&#x2013;<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00041.2003</pub-id>
</citation>
</ref>
<ref id="B121">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owens</surname>
<given-names>G. K.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Regulation of differentiation of vascular smooth muscle cells</article-title>. <source>Physiol. Rev.</source> <volume>75</volume>, <fpage>487</fpage>&#x2013;<lpage>517</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.1995.75.3.487</pub-id>
</citation>
</ref>
<ref id="B122">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papaioannou</surname>
<given-names>V. E.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>The T-box gene family: Emerging roles in development, stem cells and cancer</article-title>. <source>Development</source> <volume>141</volume>, <fpage>3819</fpage>&#x2013;<lpage>3833</lpage>. <pub-id pub-id-type="doi">10.1242/dev.104471</pub-id>
</citation>
</ref>
<ref id="B123">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Schermuly</surname>
<given-names>R. T.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>Y. S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Sox17 deficiency promotes pulmonary arterial hypertension via HGF/c-Met signaling</article-title>. <source>Circ. Res.</source> <volume>131</volume>, <fpage>792</fpage>&#x2013;<lpage>806</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.122.320845</pub-id>
</citation>
</ref>
<ref id="B124">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paulin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Courboulin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Meloche</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mainguy</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Dumas de la Roque</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Saksouk</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension</article-title>. <source>Circulation</source> <volume>123</volume>, <fpage>1205</fpage>&#x2013;<lpage>1215</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.963314</pub-id>
</citation>
</ref>
<ref id="B125">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paulin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Meloche</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bonnet</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>STAT3 signaling in pulmonary arterial hypertension</article-title>. <source>JAKSTAT</source> <volume>1</volume>, <fpage>223</fpage>&#x2013;<lpage>233</lpage>. <pub-id pub-id-type="doi">10.4161/jkst.22366</pub-id>
</citation>
</ref>
<ref id="B126">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qian</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Gou</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>PDGFBB promotes proliferation and migration via regulating miR-1181/STAT3 axis in human pulmonary arterial smooth muscle cells</article-title>. <source>Am. J. Physiol. Lung Cell Mol. Physiol.</source> <volume>315</volume>, <fpage>L965</fpage>&#x2013;<lpage>L976</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00224.2018</pub-id>
</citation>
</ref>
<ref id="B127">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rabinovitch</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guignabert</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Humbert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nicolls</surname>
<given-names>M. R.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension</article-title>. <source>Circ. Res.</source> <volume>115</volume>, <fpage>165</fpage>&#x2013;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.113.301141</pub-id>
</citation>
</ref>
<ref id="B128">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ranchoux</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Antigny</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Rucker-Martin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hautefort</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pechoux</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bogaard</surname>
<given-names>H. J.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Endothelial-to-Mesenchymal transition in pulmonary hypertension</article-title>. <source>Circulation</source> <volume>131</volume>, <fpage>1006</fpage>&#x2013;<lpage>1018</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.008750</pub-id>
</citation>
</ref>
<ref id="B129">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reyfman</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Anekalla</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>McQuattie-Pimentel</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis</article-title>. <source>Am. J. Respir. Crit. Care Med.</source> <volume>199</volume>, <fpage>1517</fpage>&#x2013;<lpage>1536</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201712-2410OC</pub-id>
</citation>
</ref>
<ref id="B130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rhodes</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Batai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bleda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Haimel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Southgate</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Germain</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Genetic determinants of risk in pulmonary arterial hypertension: International genome-wide association studies and meta-analysis</article-title>. <source>Lancet Resp. Med.</source> <volume>7</volume>, <fpage>227</fpage>&#x2013;<lpage>238</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(18)30409-0</pub-id>
</citation>
</ref>
<ref id="B131">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruffenach</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chabot</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tanguay</surname>
<given-names>V. F.</given-names>
</name>
<name>
<surname>Courboulin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Boucherat</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Potus</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Role for runt-related transcription factor 2 in proliferative and calcified vascular lesions in pulmonary arterial hypertension</article-title>. <source>Am. J. Respir. Crit. Care Med.</source> <volume>194</volume>, <fpage>1273</fpage>&#x2013;<lpage>1285</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201512-2380OC</pub-id>
</citation>
</ref>
<ref id="B132">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahoo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>de Jesus</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sembrat</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rojas</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Goncharova</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Notch2 suppression mimicking changes in human pulmonary hypertension modulates Notch1 and promotes endothelial cell proliferation</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol.</source> <volume>321</volume>, <fpage>H542</fpage>&#x2013;<lpage>H557</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00125.2021</pub-id>
</citation>
</ref>
<ref id="B133">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Taraseviciene-Stewart</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cool</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>Voelkel</surname>
<given-names>N. F.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells</article-title>. <source>FASEB J.</source> <volume>19</volume>, <fpage>1178</fpage>&#x2013;<lpage>1180</lpage>. <pub-id pub-id-type="doi">10.1096/fj.04-3261fje</pub-id>
</citation>
</ref>
<ref id="B134">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sauler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bazan</surname>
<given-names>I. S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>P. J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Cell death in the lung: The apoptosis-necroptosis Axis</article-title>. <source>Annu Rev. Physiol.</source> <volume>81</volume>, <fpage>375</fpage>&#x2013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-physiol-020518-114320</pub-id>
</citation>
</ref>
<ref id="B135">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savai</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Al-Tamari</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Sedding</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kojonazarov</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Muecke</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Teske</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension</article-title>. <source>Nat. Med.</source> <volume>20</volume>, <fpage>1289</fpage>&#x2013;<lpage>1300</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3695</pub-id>
</citation>
</ref>
<ref id="B136">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savai</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pullamsetti</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Kolbe</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bieniek</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Voswinckel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fink</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension</article-title>. <source>Am. J. Resp. Crit. Care</source> <volume>186</volume>, <fpage>897</fpage>&#x2013;<lpage>908</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201202-0335OC</pub-id>
</citation>
</ref>
<ref id="B137">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Semenza</surname>
<given-names>G. L.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Hypoxia-inducible factors in physiology and medicine</article-title>. <source>Cell</source> <volume>148</volume>, <fpage>399</fpage>&#x2013;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.01.021</pub-id>
</citation>
</ref>
<ref id="B138">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shao</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J. X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D. Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q. H.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Potential contribution of early endothelial progenitor cell (eEPC)-to-macrophage switching in the development of pulmonary plexogenic lesion</article-title>. <source>Resp. Res.</source> <volume>23</volume>, <fpage>290</fpage>. <pub-id pub-id-type="doi">10.1186/s12931-022-02210-7</pub-id>
</citation>
</ref>
<ref id="B139">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheak</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>D. T.</given-names>
</name>
<name>
<surname>Lantz</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Maston</surname>
<given-names>L. D.</given-names>
</name>
<name>
<surname>Vigil</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Resta</surname>
<given-names>T. C.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>NFATc3 regulation of collagen V expression contributes to cellular immunity to collagen type V and hypoxic pulmonary hypertension</article-title>. <source>Am. J. Physiol-Lung C</source> <volume>319</volume>, <fpage>L968</fpage>&#x2013;<lpage>L980</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00184.2020</pub-id>
</citation>
</ref>
<ref id="B140">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>GSDMD-mediated cardiomyocyte pyroptosis promotes myocardial I/R injury</article-title>. <source>Circ. Res.</source> <volume>129</volume>, <fpage>383</fpage>&#x2013;<lpage>396</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.318629</pub-id>
</citation>
</ref>
<ref id="B141">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Pyroptosis: Gasdermin-Mediated programmed necrotic cell death</article-title>. <source>Trends Biochem Sci.</source> <volume>42</volume>, <fpage>245</fpage>&#x2013;<lpage>254</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2016.10.004</pub-id>
</citation>
</ref>
<ref id="B142">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simonneau</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Montani</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Celermajer</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Denton</surname>
<given-names>C. P.</given-names>
</name>
<name>
<surname>Gatzoulis</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Krowka</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Haemodynamic definitions and updated clinical classification of pulmonary hypertension</article-title>. <source>Eur. Respir. J.</source> <volume>53</volume>, <fpage>1801913</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.01913-2018</pub-id>
</citation>
</ref>
<ref id="B143">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sobue</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nishida</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Expressional regulation of smooth muscle cell-specific genes in association with phenotypic modulation</article-title>. <source>Mol. Cell Biochem</source> <volume>190</volume>, <fpage>105</fpage>&#x2013;<lpage>118</lpage>. <pub-id pub-id-type="doi">10.1023/a:1006941621170</pub-id>
</citation>
</ref>
<ref id="B144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soubrier</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>W. K.</given-names>
</name>
<name>
<surname>Machado</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Grunig</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Aldred</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Geraci</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Genetics and genomics of pulmonary arterial hypertension</article-title>. <source>J. Am. Coll. Cardiol.</source> <volume>62</volume>, <fpage>D13</fpage>&#x2013;<lpage>D21</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2013.10.035</pub-id>
</citation>
</ref>
<ref id="B145">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Southgate</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Machado</surname>
<given-names>R. D.</given-names>
</name>
<name>
<surname>Graf</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Morrell</surname>
<given-names>N. W.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Molecular genetic framework underlying pulmonary arterial hypertension</article-title>. <source>Nat. Rev. Cardiol.</source> <volume>17</volume>, <fpage>85</fpage>&#x2013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1038/s41569-019-0242-x</pub-id>
</citation>
</ref>
<ref id="B146">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stenmark</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Fagan</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Frid</surname>
<given-names>M. G.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Hypoxia-induced pulmonary vascular remodeling: Cellular and molecular mechanisms</article-title>. <source>Circ. Res.</source> <volume>99</volume>, <fpage>675</fpage>&#x2013;<lpage>691</lpage>. <pub-id pub-id-type="doi">10.1161/01.RES.0000243584.45145.3f</pub-id>
</citation>
</ref>
<ref id="B147">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stockinger</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Di Meglio</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gialitakis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Duarte</surname>
<given-names>J. H.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>The aryl hydrocarbon receptor: Multitasking in the immune system</article-title>. <source>Annu Rev. Immunol.</source> <volume>32</volume>, <fpage>403</fpage>&#x2013;<lpage>432</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120245</pub-id>
</citation>
</ref>
<ref id="B148">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cong</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Hypoxia inducible factor-1 alpha-induced interleukin-33 expression in intestinal epithelia contributes to mucosal homeostasis in inflammatory bowel disease</article-title>. <source>Clin. Exp. Immunol.</source> <volume>187</volume>, <fpage>428</fpage>&#x2013;<lpage>440</lpage>. <pub-id pub-id-type="doi">10.1111/cei.12896</pub-id>
</citation>
</ref>
<ref id="B149">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>X. G.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>Babicheva</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vanderpool</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Oita</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Casanova</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Direct extracellular NAMPT involvement in pulmonary hypertension and vascular remodeling. Transcriptional regulation by SOX and HIF-2&#x3b1;</article-title>. <source>Am. J. Resp. Cell Mol.</source> <volume>63</volume>, <fpage>92</fpage>&#x2013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2019-0164OC</pub-id>
</citation>
</ref>
<ref id="B150">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sutendra</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dromparis</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bonnet</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Haromy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension</article-title>. <source>Sci. Transl. Med.</source> <volume>3</volume>, <fpage>88ra55</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3002194</pub-id>
</citation>
</ref>
<ref id="B151">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sylvester</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Shimoda</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Aaronson</surname>
<given-names>P. I.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>J. P. T.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Hypoxic pulmonary vasoconstriction</article-title>. <source>Physiol. Rev.</source> <volume>92</volume>, <fpage>367</fpage>&#x2013;<lpage>520</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00041.2010</pub-id>
</citation>
</ref>
<ref id="B152">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tajsic</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Morrell</surname>
<given-names>N. W.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension</article-title>. <source>Compr. Physiol.</source> <volume>1</volume>, <fpage>295</fpage>&#x2013;<lpage>317</lpage>. <pub-id pub-id-type="doi">10.1002/cphy.c100026</pub-id>
</citation>
</ref>
<ref id="B153">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Talati</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gladson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Blackwell</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shay</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hamid</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>West</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Macrophages are part of cause, not consequence, in PAH</article-title>. <source>FASEB J.</source> <volume>30</volume>, <fpage>774.12</fpage>. <pub-id pub-id-type="doi">10.1096/fasebj.30.1_supplement.774.12</pub-id>
</citation>
</ref>
<ref id="B154">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamosiuniene</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Manouvakhova</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Mesange</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sanyal</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Dominant role for regulatory T cells in protecting females against pulmonary hypertension</article-title>. <source>Circ. Res.</source> <volume>122</volume>, <fpage>1689</fpage>&#x2013;<lpage>1702</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.312058</pub-id>
</citation>
</ref>
<ref id="B155">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamosiuniene</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Dhillon</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>Y. K.</given-names>
</name>
<name>
<surname>Gera</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension</article-title>. <source>Circ. Res.</source> <volume>109</volume>, <fpage>867</fpage>&#x2013;<lpage>879</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.236927</pub-id>
</citation>
</ref>
<ref id="B156">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Babicheva</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>McDermott</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>Y. L.</given-names>
</name>
<name>
<surname>Ayon</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>S. S.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Endothelial HIF-2 alpha contributes to severe pulmonary hypertension due to endothelial-to-mesenchymal transition</article-title>. <source>Am. J. Physiol-Lung C</source> <volume>314</volume>, <fpage>L256</fpage>&#x2013;<lpage>L275</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00096.2017</pub-id>
</citation>
</ref>
<ref id="B157">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taraseviciene-Stewart</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nicolls</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Kraskauskas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Scerbavicius</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cool</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling</article-title>. <source>Am. J. Resp. Crit. Care</source> <volume>175</volume>, <fpage>1280</fpage>&#x2013;<lpage>1289</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.200608-1189OC</pub-id>
</citation>
</ref>
<ref id="B158">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teichert-Kuliszewska</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kutryk</surname>
<given-names>M. J. B.</given-names>
</name>
<name>
<surname>Kuliszewski</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Karoubi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Courtman</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Zucco</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival - implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension</article-title>. <source>Circ. Res.</source> <volume>98</volume>, <fpage>209</fpage>&#x2013;<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1161/01.RES.0000200180.01710.e6</pub-id>
</citation>
</ref>
<ref id="B159">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thenappan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Weir</surname>
<given-names>E. K.</given-names>
</name>
</person-group> (<year>2018a</year>). <article-title>Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol.</source> <volume>315</volume>, <fpage>H1322</fpage>&#x2013;<lpage>H1331</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00136.2018</pub-id>
</citation>
</ref>
<ref id="B160">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thenappan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ormiston</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Archer</surname>
<given-names>S. L.</given-names>
</name>
</person-group> (<year>2018b</year>). <article-title>Pulmonary arterial hypertension: Pathogenesis and clinical management</article-title>. <source>BMJ</source> <volume>360</volume>, <fpage>j5492</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.j5492</pub-id>
</citation>
</ref>
<ref id="B161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname>
<given-names>A. A. R.</given-names>
</name>
<name>
<surname>Lawrie</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Targeting vascular remodeling to treat pulmonary arterial hypertension</article-title>. <source>Trends Mol. Med.</source> <volume>23</volume>, <fpage>31</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2016.11.005</pub-id>
</citation>
</ref>
<ref id="B162">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Udjus</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cero</surname>
<given-names>F. T.</given-names>
</name>
<name>
<surname>Halvorsen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Behmen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Bendiksen</surname>
<given-names>B. A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Caspase-1 induces smooth muscle cell growth in hypoxia-induced pulmonary hypertension</article-title>. <source>Am. J. Physiol. Lung Cell Mol. Physiol.</source> <volume>316</volume>, <fpage>L999</fpage>&#x2013;<lpage>L1012</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00322.2018</pub-id>
</citation>
</ref>
<ref id="B163">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ulrich</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Taraseviciene-Stewart</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Speich</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Voelkel</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: A cross sectional study</article-title>. <source>Respir. Res.</source> <volume>9</volume>, <fpage>20</fpage>. <pub-id pub-id-type="doi">10.1186/1465-9921-9-20</pub-id>
</citation>
</ref>
<ref id="B164">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veith</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Varturk-Ozcan</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Wujak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hadzic</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Knoepp</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>SPARC, a novel regulator of vascular cell function in pulmonary hypertension</article-title>. <source>Circulation</source> <volume>145</volume>, <fpage>916</fpage>&#x2013;<lpage>933</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.121.057001</pub-id>
</citation>
</ref>
<ref id="B165">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vergadi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>O. D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Fernandez-Gonzalez</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension</article-title>. <source>Circulation</source> <volume>123</volume>, <fpage>1986</fpage>&#x2013;<lpage>1995</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.978627</pub-id>
</citation>
</ref>
<ref id="B166">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wagner</surname>
<given-names>E. F.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun)</article-title>. <source>Ann. Rheum. Dis.</source> <volume>69</volume>, <fpage>86</fpage>&#x2013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1136/ard.2009.119396</pub-id>
</citation>
</ref>
<ref id="B167">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022a</year>). <article-title>MED1 regulates BMP/TGF-beta in endothelium: Implication for pulmonary hypertension</article-title>. <source>Circ. Res.</source> <volume>131</volume>, <fpage>828</fpage>&#x2013;<lpage>841</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.122.321532</pub-id>
</citation>
</ref>
<ref id="B168">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Q. Q.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>T. F.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y. C.</given-names>
</name>
<etal/>
</person-group> (<year>2022b</year>). <article-title>Upregulation of endothelial DKK1 (dickkopf 1) promotes the development of pulmonary hypertension through the Sp1 (specificity protein 1)/SHMT2 (serine Hydroxymethyltransferase 2) pathway</article-title>. <source>Hypertension</source> <volume>79</volume>, <fpage>960</fpage>&#x2013;<lpage>973</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.121.18672</pub-id>
</citation>
</ref>
<ref id="B169">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>T. Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M. T.</given-names>
</name>
<etal/>
</person-group> (<year>2022c</year>). <article-title>Immunity and inflammation in pulmonary arterial hypertension: From pathophysiology mechanisms to treatment perspective</article-title>. <source>Pharmacol. Res.</source> <volume>180</volume>, <fpage>106238</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2022.106238</pub-id>
</citation>
</ref>
<ref id="B170">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>G. F.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>D. Y.</given-names>
</name>
<name>
<surname>Rhen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X. K.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2022d</year>). <article-title>Reduced Notch1 cleavage promotes the development of pulmonary hypertension</article-title>. <source>Hypertension</source> <volume>79</volume>, <fpage>79</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.120.16065</pub-id>
</citation>
</ref>
<ref id="B171">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Babicheva</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Divergent changes of p53 in pulmonary arterial endothelial and smooth muscle cells involved in the development of pulmonary hypertension</article-title>. <source>Am. J. Physiol. Lung Cell Mol. Physiol.</source> <volume>316</volume>, <fpage>L216</fpage>&#x2013;<lpage>L228</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00538.2017</pub-id>
</citation>
</ref>
<ref id="B172">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiss</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Neubauer</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Yerabolu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kojonazarov</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Schlueter</surname>
<given-names>B. C.</given-names>
</name>
<name>
<surname>Neubert</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension</article-title>. <source>Nat. Commun.</source> <volume>10</volume>, <fpage>2204</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-10135-x</pub-id>
</citation>
</ref>
<ref id="B173">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>West</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>E. D.</given-names>
</name>
<name>
<surname>Gaskill</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Marriott</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Baskir</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bilousova</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Identification of a common Wnt-associated genetic signature across multiple cell types in pulmonary arterial hypertension</article-title>. <source>Am. J. Physiol. Cell Physiol.</source> <volume>307</volume>, <fpage>C415</fpage>&#x2013;<lpage>C430</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00057.2014</pub-id>
</citation>
</ref>
<ref id="B174">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilkins</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Ghofrani</surname>
<given-names>H. A.</given-names>
</name>
<name>
<surname>Weissmann</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Aldashev</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Pathophysiology and treatment of high-altitude pulmonary vascular disease</article-title>. <source>Circulation</source> <volume>131</volume>, <fpage>582</fpage>&#x2013;<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.006977</pub-id>
</citation>
</ref>
<ref id="B175">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W. T.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>Y. R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Yen</surname>
<given-names>S. J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Glucagon-like peptide-1 receptor agonist attenuates autophagy to ameliorate pulmonary arterial hypertension through Drp1/NOX- and atg-5/atg-7/beclin-1/lc3&#x3b2; pathways</article-title>. <source>Int. J. Mol. Sci.</source> <volume>20</volume>, <fpage>3435</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20143435</pub-id>
</citation>
</ref>
<ref id="B176">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Leng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022a</year>). <article-title>Caspase-4/11-Mediated pulmonary artery endothelial cell pyroptosis contributes to pulmonary arterial hypertension</article-title>. <source>Hypertension</source> <volume>79</volume>, <fpage>536</fpage>&#x2013;<lpage>548</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.121.17868</pub-id>
</citation>
</ref>
<ref id="B177">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2022b</year>). <article-title>Inhibition of KIF23 alleviates IPAH by targeting pyroptosis and proliferation of PASMCs</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume>, <fpage>4436</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23084436</pub-id>
</citation>
</ref>
<ref id="B178">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yanagisawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Osada</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Masuda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yatabe</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>1998</year>). <article-title>Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells</article-title>. <source>Oncogene</source> <volume>17</volume>, <fpage>1743</fpage>&#x2013;<lpage>1747</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1202052</pub-id>
</citation>
</ref>
<ref id="B179">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L. S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>FoxM1 promotes epithelial-mesenchymal transition, invasion, and migration of tongue squamous cell carcinoma cells through a c-Met/AKT-dependent positive feedback loop</article-title>. <source>Anti-Cancer Drug.</source> <volume>29</volume>, <fpage>216</fpage>&#x2013;<lpage>226</lpage>. <pub-id pub-id-type="doi">10.1097/CAD.0000000000000585</pub-id>
</citation>
</ref>
<ref id="B180">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Al-Lamki</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Southwood</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lever</surname>
<given-names>A. M.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells <italic>in vitro</italic> and <italic>in vivo</italic>
</article-title>. <source>Circ. Res.</source> <volume>107</volume>, <fpage>252</fpage>&#x2013;<lpage>262</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.209940</pub-id>
</citation>
</ref>
<ref id="B181">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>K. J.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>TWIST activation by hypoxia inducible factor-1 (HIF-1): Implications in metastasis and development</article-title>. <source>Cell Cycle</source> <volume>7</volume>, <fpage>2090</fpage>&#x2013;<lpage>2096</lpage>. <pub-id pub-id-type="doi">10.4161/cc.7.14.6324</pub-id>
</citation>
</ref>
<ref id="B182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>J. G.</given-names>
</name>
<name>
<surname>Skayian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ochani</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>E. J.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Deletion of STAT5a/b in vascular smooth muscle abrogates the male bias in hypoxic pulmonary hypertension in mice: Implications in the human disease</article-title>. <source>Mol. Med.</source> <volume>20</volume>, <fpage>625</fpage>&#x2013;<lpage>638</lpage>. <pub-id pub-id-type="doi">10.2119/molmed.2014.00180</pub-id>
</citation>
</ref>
<ref id="B183">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yerabolu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kojonazarov</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Boehm</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schlueter</surname>
<given-names>B. C.</given-names>
</name>
<name>
<surname>Ruppert</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Targeting jak-stat signaling in experimental pulmonary hypertension</article-title>. <source>Am. J. Respir. Cell Mol. Biol.</source> <volume>64</volume>, <fpage>100</fpage>&#x2013;<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2019-0431OC</pub-id>
</citation>
</ref>
<ref id="B184">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshida</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Uchida</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kodo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Furutani</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Genetic and functional analyses of TBX4 reveal novel mechanisms underlying pulmonary arterial hypertension</article-title>. <source>J. Mol. Cell Cardiol.</source> <volume>171</volume>, <fpage>105</fpage>&#x2013;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2022.07.002</pub-id>
</citation>
</ref>
<ref id="B185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>X. F.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X. X.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X. D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X. J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Growth differentiation factor 11 promotes abnormal proliferation and angiogenesis of pulmonary artery endothelial cells</article-title>. <source>Hypertension</source> <volume>71</volume>, <fpage>729</fpage>&#x2013;<lpage>741</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.117.10350</pub-id>
</citation>
</ref>
<ref id="B186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yue</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y. Q.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y. T.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Osthole inhibits cell proliferation by regulating the TGF-&#x3b2;1/Smad/p38 signaling pathways in pulmonary arterial smooth muscle cells</article-title>. <source>Biomed. Pharmacother.</source> <volume>121</volume>, <fpage>109640</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2019.109640</pub-id>
</citation>
</ref>
<ref id="B187">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zabini</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Granton</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Miranda</surname>
<given-names>M. Z.</given-names>
</name>
<name>
<surname>Weichelt</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Breuils Bonnet</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Loss of SMAD3 promotes vascular remodeling in pulmonary arterial hypertension via MRTF disinhibition</article-title>. <source>Am. J. Respir. Crit. Care Med.</source> <volume>197</volume>, <fpage>244</fpage>&#x2013;<lpage>260</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201702-0386OC</pub-id>
</citation>
</ref>
<ref id="B188">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zaloudikova</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vytasek</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vajnerova</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Hnilickova</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Vizek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hampl</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Depletion of alveolar macrophages attenuates hypoxic pulmonary hypertension but not hypoxia-induced increase in serum concentration of MCP-1</article-title>. <source>Physiol. Res.</source> <volume>65</volume>, <fpage>763</fpage>&#x2013;<lpage>768</lpage>. <pub-id pub-id-type="doi">10.33549/physiolres.933187</pub-id>
</citation>
</ref>
<ref id="B189">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zamzami</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kroemer</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>The mitochondrion in apoptosis: How pandora&#x27;s box opens</article-title>. <source>Nat. Rev. Mol. Cell Bio</source> <volume>2</volume>, <fpage>67</fpage>&#x2013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1038/35048073</pub-id>
</citation>
</ref>
<ref id="B190">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zawia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>N. D.</given-names>
</name>
<name>
<surname>West</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pickworth</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Turton</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Iremonger</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Altered macrophage polarization induces experimental pulmonary hypertension and is observed in patients with pulmonary arterial hypertension</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source> <volume>41</volume>, <fpage>430</fpage>&#x2013;<lpage>445</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.120.314639</pub-id>
</citation>
</ref>
<ref id="B191">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z. C.</given-names>
</name>
</person-group> (<year>2018a</year>). <article-title>Hypoxia induces endothelial-mesenchymal transition in pulmonary vascular remodeling</article-title>. <source>Int. J. Mol. Med.</source> <volume>42</volume>, <fpage>270</fpage>&#x2013;<lpage>278</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2018.3584</pub-id>
</citation>
</ref>
<ref id="B192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>X. X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Gui</surname>
<given-names>L. X.</given-names>
</name>
<etal/>
</person-group> (<year>2018b</year>). <article-title>Galectin-3-Mediated transdifferentiation of pulmonary artery endothelial cells contributes to hypoxic pulmonary vascular remodeling</article-title>. <source>Cell Physiol. Biochem</source> <volume>51</volume>, <fpage>763</fpage>&#x2013;<lpage>777</lpage>. <pub-id pub-id-type="doi">10.1159/000495331</pub-id>
</citation>
</ref>
<ref id="B193">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation</article-title>. <source>Cell Prolif.</source> <volume>53</volume>, <fpage>e12742</fpage>. <pub-id pub-id-type="doi">10.1111/cpr.12742</pub-id>
</citation>
</ref>
<ref id="B194">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Oliver</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Maratou</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Atanur</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Dubois</surname>
<given-names>O. D.</given-names>
</name>
<name>
<surname>Cotroneo</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia</article-title>. <source>Nature</source> <volume>524</volume>, <fpage>356</fpage>&#x2013;<lpage>360</lpage>. <pub-id pub-id-type="doi">10.1038/nature14620</pub-id>
</citation>
</ref>
<ref id="B195">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Established pulmonary hypertension in rats was reversed by a combination of a HIF-2&#x3b1; antagonist and a p53 agonist</article-title>. <source>Br. J. Pharmacol.</source> <volume>179</volume>, <fpage>1065</fpage>&#x2013;<lpage>1081</lpage>. <pub-id pub-id-type="doi">10.1111/bph.15696</pub-id>
</citation>
</ref>
<ref id="B196">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Welch</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Gonzaga-Jauregui</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>L. J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease</article-title>. <source>Genome Med.</source> <volume>10</volume>, <fpage>56</fpage>. <pub-id pub-id-type="doi">10.1186/s13073-018-0566-x</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>